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Abstract
1Caﬀeine is one of the most pervasively ingested addictive substances in the United States, yet
astoundingly little attention is paid to its ubiquitous presence. This Paper examines caﬀeine,
the substance, from many perspectives. First, it discusses caﬀeine with particular regard to
its chemical properties; its presence in foods, beverages, and medications both naturally and
as an additive; and its known impacts on human biological and psychological functioning.
Relevant medical investigations of caﬀeine’s therapeutic properties and its toxicology are
included in order to better evaluate the beneﬁts, the risks, and the relative safety of prolonged
caﬀeine consumption. In light of more recent medical ﬁndings, the Paper ﬁnds that caﬀeine
poses fewer serious health risks than previously thought, and the potential for damage to the
vast majority of the consumer public is minimal.
The Paper also addresses issues of FDA regulation of caﬀeine, including a discussion
of current regulation and classiﬁcation of the substance both as a food product and as a
drug product, as well as questioning the usefulness of greater consumer warning labels and
promotion of improved public awareness of caﬀeine’s various health eﬀects. Due to both the
paucity of long-term caﬀeine health studies and the conﬂicts among those studies, the Paper
contends that heightened FDA regulatory scrutiny of American caﬀeine consumption is an
unnecessary expenditure of limited resources. The Paper ﬁnds caﬀeine poses no material
danger to the consumer, and dismisses the claims of prior authors to that eﬀect as generally
overstated. Finally, the Paper poses a hypothetical analysis of caﬀeine as both a new food
additive and a new drug, in order to illustrate the FDA’s modern regulatory process and
demonstrate greater conﬁdence in the safety of consumer caﬀeine use.
2I. Introduction: Caﬀeine – The American Crutch
Picture this: a group of people are seated and quietly reading the morning newspaper in the nearby corner
“Starbucks” coﬀee shop while sipping a “Grande Latte.”1 Elsewhere, a team of frenetic business executives
dash to the closest street vendor to grab a quick cup of black coﬀee or a “Diet Coke” to wake up for the
next morning business meeting.2 In dormitory rooms on college campuses everywhere, students sit staring
at computer screens while drinking a wide variety of caﬀeinated beverages, or even ingesting OTC drugs like
“Vivarin” to stay awake and ﬁnish the occasional all-night assignment.3 In a quiet teahouse, people debate
philosophy over a cup of Assam or Darjeeling black tea. Whether used as a day-starter, a work ﬁnisher, or a
recreational excuse for conversation, substances containing caﬀeine have developed a certain contemporary
cachet in American society, though they have been available for centuries.4
On the other hand, ever-increasing consumer vigilance regarding individual health causes many people to
wonder about the addictive and potentially dangerous properties of caﬀeinated products. For a drug so
commonly used, little attention is paid to the chemical itself, its abundant sources both in nature and in
synthetics, the quantity of caﬀeine ingested on a daily basis, and the real eﬀects of caﬀeine use (both short
1“Starbucks” refers to the Starbucks Corporation, and “Grande Latte” is a proprietary designation.
2“Diet Coke” is a trademarked product of the Coca Cola Corporation.
3“Vivarin” is a trademarked over-the-counter caﬀeine pill.
4See Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill Health Profes-
sions Division (1996), at 672 (“The basis for the popularity of all the caﬀeine-containing beverages is the ancient belief that
they have stimulant and antisoporiﬁc actions that elevate mood, decrease fatigue, and increase capacity for work. For example,
legend credits the discovery of coﬀee to a prior of an Arabian convent. Shepherds reported that goats that had eaten the berries
of the coﬀee plant gamboled and frisked about all through the night instead of sleeping. The prior, mindful of the long nights
of prayer that he had to endure, instructed the shepherds to pick the berries so that he might make a beverage from them”).
See also “Caﬀeine and Women’s Health,” International Food Information Council Publications (Aug. 2002), available
at http://iﬁc.org/publications/brochures/caﬀwomenbroch.cfm; (“As long ago as 2,700 B.C. the Chinese Emperor Shen Nung
sipped hot brewed tea. Coﬀee’s origins date back to 575 A.D. when in Africa beans were used as money and consumed as
food”).
3and long term). These issues are now discussed in detail.
II. Understanding Caﬀeine: The Drug and Its Eﬀects
A. Caﬀeine: The Chemical and its Sources
Caﬀeine is now thought to be “the most widely used psychoactive drug in the world.”5 Some studies estimate
that 90% or more of this country’s population uses caﬀeine, whether through foods, beverages, or prescription
and over-the-counter medicines.6 The most common sources of caﬀeine for Americans include brewed coﬀee,
brewed tea, typical cola drinks, milk and dark chocolate, and over-the-counter medications like “Anacin”
and “Vivarin.”7
Caﬀeine is an alkaloid, or nitrogen-containing substance, bearing the chemical formula C8H10N4O2.8 It
belongs to the family of chemicals known as methylxanthines, which also includes the closely related chemicals
theophylline and theobromine.9 In its pure form, caﬀeine “occurs as odorless, white, ﬂeecy masses, glistening
needles or powder.”10 As with all methylxanthines, caﬀeine has low solubility and is therefore often combined
with a wide variety of compounds to form complexes, such as the double salt sodium benzoate, for purposes
5Goodman & Gilman, supra note 4 at 571. See also Prothro, supra note 5 at 66: (“Caﬀeine is one of the most widely used
psychoactive substances in the United States and the world today”). See generally Jerome H. Jaﬀe, “Psychoactive Substance
Use Disorders,” in Comprehensive Textbook of Psychiatry, 642, 683 (1989).
6See Brain, supra note 14.
7See Id.
8Prothro, Gwendolyn, “The Caffeine Conundrum: Caffeine Consumption and Regulation in the United States,” 27
Cumb. L. Rev. 65, 66 (1996/1997).
9See “Wikipedia, the Free Encyclopedia – Caﬀeine,” available at http://en.wikipedia.org/wiki/Caﬀeine.
10Id.
4of enhanced solubility in consumer goods like soft drinks.11
Caﬀeine and the other methylxanthines are found in nature “in plants widely distributed geographically.”12
Tea, which is prepared from the leaves of the plant Thea sunensis, naturally contains all three of the
aforementioned methylxanthines and is consumed by at least half of the entire world population.13 Cocoa
and chocolate are produced “from the seeds of Theobroma cacao”; both contain caﬀeine and theobromine,
and both are used the world over.14 The most obvious and important source of American caﬀeine intake,
coﬀee, is produced from the Coﬀea arabica plant.15 Prior to the deliberate insertion of additional caﬀeine
during production, many sodas contain a natural form of caﬀeine “because of their content of extracts of the
nuts of Cola acuminata.”16 While it occurs abundantly in nature from a wide variety of sources, caﬀeine is
also “created synthetically and by extraction from cocoa, coﬀee bean or tea leaf waste,” which allows for its
inclusion in a greater variety of consumer products.17
B. Caﬀeine Dosages: Quantity in Consumer Products
It is diﬃcult to arrive at a recommended ordinary consumption quantity, or a standard “dose,” since caﬀeine
is present in various consumer goods at widely diﬀering levels. Some sources suggest that one-hundred
11Goodman & Gilman, supra note 4 at 673.
12Id. at 672.
13Id. (“Thea sunensis, a bush native to southern China and now extensively cultivated in other countries”).
14Id. A separate but relevant subject of study involves the combination and interaction eﬀects of the methylxanthines as a
group; since products like tea and cocoa contain multiple methylxanthines, an elevated (or perhaps conﬂicting) set of eﬀects
could be observed.
15See Id.
16Id. See also “What is Caﬀeine,” Glossary of Food Related Terms, available at http://ozans.4mg.com/glossary.htm:
(“Caﬀeine is a naturally-occurring substance found in the leaves, seeds or fruits of over 63 plant species worldwide”).
17See Prothro, supra note 5 at 66. See also Marshall Brain, “How Caﬀeine Works,” available at
http://health.howstuﬀworks.com/caﬀeine1.htm: (“The chief source of pure caﬀeine is the process of decaﬀeinating coﬀee and
tea”).
5milligrams, whether delivered into the bloodstream by liquid or solid, is useful as a base-line single dosage.18
Though caﬀeine content can diﬀer markedly even within a product category, (for example, the amount
of caﬀeine present in “real-world coﬀee” can range from seventy-ﬁve to two-hundred-ﬁfty milligrams per
serving), the rough quantity of caﬀeine in the most commonly ingested products is well known.19
A standard six ounce cup of drip-brewed coﬀee contains roughly one-hundred milligrams of caﬀeine, whereas
a similarly sized cup of brewed tea contains roughly seventy milligrams.20 Espresso, a common ingredient
in many of today’s popular specialty coﬀee drinks, contains closer to one-hundred milligrams of caﬀeine per
liquid ounce.21 A conventional twelve ounce can of soda contains approximately ﬁfty milligrams of caﬀeine,
though specialty sodas such as “Jolt Cola” contain closer to seventy milligrams.22 Milk chocolate contains
roughly six milligrams of caﬀeine per ounce.23 In the most common over-the-counter drugs, “Anacin” and
“Excedrin” tablets contain thirty-two milligrams of caﬀeine each, while “Vivarin” contains two-hundred
milligrams per tablet.24
More noteworthy than the speciﬁc quantity of caﬀeine in conventional consumer products is the quantity of
each product ingested on a daily basis. While the customary six ounce cup of coﬀee may contain one-hundred
milligrams of caﬀeine, the ordinary serving sizes of “Starbucks” coﬀees are twelve, sixteen, and twenty ounces
each.25 More than half of all adult Americans “drink an average of three and a half cups of coﬀee a day,
18See “Wikipedia,” supra note 6.
19Id.
20Brain, supra note 14.
21“Wikipedia,” supra note 6.
22Id.
23See generally Brain, supra note 14.
24Id.
25Sizing information corresponds to the Starbucks Corporation’s usage of the terminology “Tall,” “Grande,” and “Venti,”
which are twelve, sixteen, and twenty ounce sizes respectively.
6in addition to tea, cola, chocolate and over-the-counter caﬀeine-containing drugs.”26 If potential problems
with adult caﬀeine consumption are an issue to be considered, the caﬀeine intake of children is even more
important, because “the potency of caﬀeine on a human body depends on the body’s weight.”27 Some
sources suggest that “[t]he highest exposure to caﬀeine from soft drinks on a mg/ kg / day basis is among
young children,” especially children under the age of six.28
C. Caﬀeine Consumption I: Therapeutic Uses and Positive Mechanics
Since so many people are consuming so much caﬀeine on a daily basis, the short and long-term beneﬁcial
eﬀects of such usage merit signiﬁcant discussion.29 Caﬀeine has a variety of pharmacological eﬀects on organ
systems and neural functions, “though the level and duration of the eﬀect varies among bodies.”30 It is
absorbed into the bloodstream following ingestion via the lining of the stomach and the small intestine,
and reaches peak levels in the circulation of the bloodstream between ﬁfteen and forty-ﬁve minutes after
consumption.31 Caﬀeine stimulates the central nervous system, reaching its maximum eﬀect between thirty
and sixty minutes after absorption; this is accompanied by a temporary increase in metabolic function.32 It
also relaxes smooth muscle, particularly bronchial muscle, which accounts for its inclusion in a wide variety
of asthma medications.33
26Prothro, supra note 5 at 68. Citing Ed Blonz, “The Buzz About Caﬀeine,” Better Homes and Gardens, May 1995, at 50.
27Id. at 70.
2845 Fed. Reg. 69,817, 69,820 (1980). Cited in Prothro, supra note 5 at 68.
29See Brain, supra note 14: (“More than half of all American adults consume more than 300 milligrams (mg) of caﬀeine
every day, making it America’s most popular drug by far”).
30Prothro, supra note 5 at 67.
31See Id.
32Id.
33Goodman & Gilman, supra note 4 at 677: (“Preparations are employed to relax bronchial smooth muscle in the treatment
of asthma and to relieve dyspnea in the treatment of chronic obstructive pulmonary disease”).
7Initially, caﬀeine’s therapeutic application to small children was diﬃcult; infants have incredible diﬃculty
metabolizing caﬀeine until at least three to ﬁve months of age, while younger infants may be entirely unable
to process it, and generally excrete it unchanged.34 However, caﬀeine has found new popularity “in the
treatment of the prolonged apnea that is sometimes observed in preterm infants.”35 Though the long-term
eﬀects of caﬀeine administration on infant growth and development are not entirely known, no negative
correlations between infant development and caﬀeine use have been detected as yet.36
Caﬀeine has long been employed medically “as a mild diuretic,” meaning it increases the body’s ability
to produce urine; this is precisely the rationale behind its inclusion in certain medications for menopausal
women who are suﬀering from water retention.37 Caﬀeine also acts as a stimulant for the cardiovascular
system, though “[t]he actions of the methylxanthines on the circulatory system are complex and sometimes
antagonistic, and the resulting eﬀects largely depend on the conditions prevailing at the time of their admin-
istration.”38 Higher concentrations of caﬀeine have been known to produce tachycardia and other cardiac
arrhythmias, but the risk of this in normal healthy individuals is minimal.39
These pharmacological eﬀects last only as long as caﬀeine remains in the bloodstream; as time progresses
following ingestion and absorption, the liver metabolizes the caﬀeine.40 It is then excreted from the body
through a number of channels, including urine, saliva, semen, and even breast milk.41 While a number of fac-
34See Alejandro Lopez-Ortiz, “Frequently Asked Questions About Coﬀee and Caﬀeine,” available at
http://www.lib.ox.ac.uk/internet/news/faq/archive/caﬀeine-faq.html. Cited in Prothro, supra note 5 at 67.
35Goodman & Gilman, supra note 4 at 677.
36See Id.
37Brain, supra note 14. See generally “Wikipedia,” supra note 6. See also Goodman and Gilman, supra note 4 at 677: (“Caf-
feine, in probably subtherapeutic amounts, is incorporated into a number of over-the-counter preparations used for analgesia
or to produce diuresis”).
38See Goodman & Gilman, supra note 4 at 674: (“In addition to eﬀects on the vagal and vasomotor centers in the brain
stem, there is an array of more or less direct actions on vascular and cardiac tissues, in combination with indirect peripheral
actions that are mediated by catecholamines and possibly by the rennin-angiotensin system. Therefore, the observation of a
single function, for example, the blood pressure, is deceiving because the drugs may act on a variety of circulatory factors in
such a way that the blood pressure may remain essentially unchanged”).
39Id.
40See generally Goodman & Gilman, supra note 4.
41See Lopez-Ortiz, supra note 34.
8tors, among which are pregnancy, liver disease, body weight, concurrent medications, and natural metabolic
rate all inﬂuence the body’s ability to break down caﬀeine, “its average half-life is three and one half hours,”
meaning that the average person will eliminate half of the amount of ingested caﬀeine within that time
span.42 Fortunately, caﬀeine is “quickly and completely removed from the brain and, unlike other central
nervous system stimulants or alcohol, its eﬀects are short lived.”43 Additionally, “caﬀeine does not aﬀect
concentration or higher mental functions, and hence caﬀeinated drinks are often consumed in the course of
work.”44
Put simply, people predominantly use caﬀeine to help them wake up in the morning, so that they will
feel more alert and less tired. The chemical process behind this feeling of increased alertness, however, is
actually quite complex, and requires a brief discussion of the body’s sleep mechanics. In order for a person
to fall asleep, adenosine is created in the brain, which then binds itself to specialized adenosine receptors.45
This normal binding process causes drowsiness, through adenosine’s slowing down of nerve cell activity.46
Adenosine binding also simultaneously causes blood vessels in the body to dilate, presumably to increase
the oxygen ﬂow to and from the brain during the various stages of the sleep cycle.47
Caﬀeine interferes with the body’s natural tendencies to feel tired and sleep by engaging in adenosine replace-
ment; to a nerve cell, caﬀeine’s xanthine structure appears similar to adenosine, allowing the substituted
42Prothro, supra note 5 at 67. See also Lopez-Ortiz, supra note 34; the half-life of caﬀeine in the body of a pregnant woman
can be as much as eighteen to twenty hours, while caﬀeine ingested concurrently with nicotine produces faster metabolism and
a shorter half-life of three hours or so.
43“Wikipedia,” supra note 6.
44Id.
45See generally Goodman & Gilman, supra note 4.
46See generally Brain, supra note 14.
47See Id.
9binding process to occur.48 However, caﬀeine chemically stimulates nerve cell activity rather than slowing
it down, causing the familiar feeling of “lift.”49 Caﬀeine also causes the constriction of cranial blood vessels
in lieu of the dilation caused by adenosine; this is precisely the rationale for its inclusion in a variety of
over-the-counter pain relievers.50 “Pain relievers that contain caﬀeine appear to provide somewhat more
relief than caﬀeine-free products.”51
Once caﬀeine has caused the brain’s neuron ﬁring to increase rather than decrease, the pituitary gland
stimulates the adrenal gland’s release of epinephrine (adrenaline) in response to the increased activity.52
Therefore, many of the “lifting” eﬀects felt after ingesting a caﬀeinated substance are actually secondary
central nervous system eﬀects stemming from the body’s increased adrenaline production; dilated pupils,
increased respiratory capacity, elevated heart rate, and muscle tightening are all natural results of the release
of adrenaline.53 It is noteworthy that the body’s adrenaline production following signiﬁcant caﬀeine intake is
much like an emergency “ﬁght or ﬂight” response to a crisis; the body is able to generate improved short-term
mental and physical performance largely due to its being “fooled” into a state of emergency.54
The interaction between caﬀeine and dopamine is perhaps more important, and helps to explain caﬀeine’s
addictive nature. Dopamine is a neurotransmitter that activates the brain’s pleasure center.55 As with
amphetamines, caﬀeine absorption causes a reduction in the rate of dopamine reuptake, increasing the
48See Id.
49Brain, supra note 14.
50See Id. (“You can see that caﬀeine also causes the brain’s blood vessels to constrict, because it blocks adenosine’s ability
to open them up. This eﬀect is why some headache medicines like Anacin contain caﬀeine - if you have a vascular headache,
the caﬀeine will close down the blood vessels and relieve it”). In other words, caﬀeine reduces intracranial pressure to relieve
vascular headaches.
51“Caﬀeine in Pain Relievers,” Consumer Rep. on Health, July 1995, at 76.
52See Brain, supra note 14.
53See Id. See also Goodman & Gilman, supra note 4 at 674: (“Persons ingesting caﬀeine or caﬀeine-containing beverages
usually experience less drowsiness, less fatigue, and a more rapid and clearer ﬂow of thought.... As the does of caﬀeine or
theophylline is increased, signs of progressive CNS stimulation are produced...”).
54See Id.
55Brain, supra note 14.
10body’s overall dopamine level.56 Though the eﬀects are much milder with caﬀeine than with amphetamines
or strong narcotics like cocaine and heroin, the dopamine reuptake inhibiting mechanism is thought to be
much the same.57 This contributes to caﬀeine’s addictiveness; as the body receives neural signals indicating
pleasure from the intake of caﬀeine, it wants to maintain these mildly pleasurable feelings.58
D. Caﬀeine Consumption II: Addiction
The primary complaint of most consumers against caﬀeine is addictiveness. In the context of adrenaline
and dopamine production, caﬀeine causes the body to experience artiﬁcial sensations of lift and pleasure.59
In the short-term, the body beneﬁts from caﬀeine as it “restores mental alertness or wakefulness during
fatigue or drowsiness,” and helps the body remain active when rest is not an option.60 However, the levels of
adrenaline and dopamine in the body are both diminished as the majority of the substance is metabolized,
leading to fatigue and depression, and a greater desire to have another dose instead of experiencing a mood
crash.61 In the long-run, therefore, caﬀeine consumption can be a diﬃcult cycle to break, especially when
considering its short-term beneﬁts.62
The FDA has previously noted that “chronic ingestion of caﬀeine in larger than recommended doses can
lead to ‘habituation,’ which is a mild form of addiction.”63 Though signiﬁcantly milder and less damaging in
eﬀect than other related forms of addiction, recurrent caﬀeine use can cause psychological dependence in the
user.64 Physical and psychological dependence are marked by several characteristics, including “tolerance,
56Id.
57Id.
58See Id.
59Id. See generally Goodman & Gilman, supra note 4.
60See Kathleen Doheny, “Smell the Coﬀee – Just Don’t Drink Too Much,” L.A. Times, Jan. 9, 1996, at E1.
61See generally Brain, supra note 14.
62Brain, supra note 14.
6353 Fed. Reg. 6100, 6103 (1988).
64See “Wikipedia,” supra note 6. See also Eric C. Strain, et al., “Caﬀeine Dependence Syndrome: Evidence from Case
Histories and Experimental Evaluations,” 272 JAMA 1043 (1994): (“caﬀeine exhibits the features of a typical psychoactive
11withdrawal, persistent desire, or unsuccessful attempts to reduce consumption and persistent use despite
adverse psychological or physical consequences.”65
Tolerance and withdrawal are the most commonly reported indicators of caﬀeine habituation, and can take
place after ceasing to consume daily dosages of two-hundred-ﬁfty milligrams or less.66 Tolerance can occur
rapidly based on the stimulant properties of caﬀeine, suggesting that mild withdrawal symptoms may occur
even if caﬀeine has only been ingested for a short period of time.67 Withdrawal symptoms can include
“throbbing headaches, drowsiness, nausea, lethargy, irritability, nervousness, and depression,” and the onset
of these symptoms can be as early as eighteen hours after the last intake.68 A withdrawal headache, commonly
called a “caﬀeine headache,” is actually indicative of a hypersensitivity to adenosine; the sensitivity causes a
decline in blood pressure, an opening of the brain’s blood vessels, and increased intracranial pressure leading
to some sensations of pain and throbbing.69 Individuals wishing to reduce their caﬀeine dependency are
better oﬀ doing so by gradually reducing their daily intake, as withdrawal symptoms are diminished by a
gradual step-down.70
Though habituation in any form arguably poses some risk, the negative eﬀects of caﬀeine are widely disputed;
the available caﬀeine literature is marked by a continual disagreement among sources regarding the potential
long-term addictiveness (and therefore dangerousness) of the drug.71 While some sources contend that
substance of dependence”).
65See Wallace B. Pickworth, “Caﬀeine Dependence,” Lancet, Apr. 29, 1995, at 1066, cited in Prothro, supra note 5 at 73.
66Doheny, supra note 60.
67Goodman & Gilman, supra note 4 at 572.
68See Prothro, supra note 5 at 73. But see Goodman & Gilman, supra note 4 at 572: (“Although a withdrawal syndrome
can be demonstrated, few caﬀeine users report loss of control of caﬀeine intake or signiﬁcant diﬃculty in reducing or stopping
caﬀeine, if desired”).
69See “Wikipedia,” supra note 6.
70See Doheny, supra note 60.
71A notable discrepancy between sources exists when discussing the severity of caﬀeine’s addictiveness, particularly with
12caﬀeine can be a serious and compelling addiction, the American Psychiatric Association disagrees to the
extent that it has omitted caﬀeine from its listing of addicting stimulants.72 In a letter from the National
Soft Drink Association, the Journal of the American Medical Association article entitled “Caﬀeine
Dependence Syndrome” was heavily criticized for its conclusions regarding dependency.73 The letter disputes
the accuracy of the study based on its sample population, but more importantly distinguishes caﬀeine use
from other addictions because “steadily increasing doses are not associated with caﬀeine ingestion.”74 Since
caﬀeine is at least mildly addictive and has some potential for unpleasant withdrawal eﬀects, consumers
should be aware and exercise greater vigilance before consuming caﬀeinated products.
E. Caﬀeine Consumption III: Other Possible Toxicology
Irrespective of its remedial properties and its potential to cause habituation, caﬀeine is still poisonous given
a large enough dosage. Though fatalities from caﬀeine use are rare, they have occurred in the past; sixteen
fatalities were attributed to caﬀeine toxicity in the period between 1959 and 1987.75 The LD50, or “lethal
dose ﬁfty percent,” is the basis of all toxicological measurement.76 It refers to the quantity of a particular
substance that kills ﬁfty percent of a sample population, and is colloquially known as the “semi-lethal dose.”77
Caﬀeine’s LD50 is ten grams; put in terms of six ounce cups of coﬀee (each containing an estimated one-
hundred milligrams of caﬀeine), fatality may result if approximately one-hundred cups of coﬀee are ingested
within a very short period of time.78
regard to frequency and severity of withdrawal symptoms following cessation of caﬀeine intake. Based on the descriptions of
caﬀeine’s medical eﬀects in Goodman & Gilman, it is a reasonable conclusion that the known dangers of caﬀeine have been
overstated in numerous other sources.
72See Goodman & Gilman, supra note 4 at 572: (“Thus caﬀeine is not listed in the category of addicting stimulants”), citing
a 1994 APA report.
73Richard H. Adamson & Howard R. Roberts, “Letter: Caﬀeine Dependence Syndrome,” 273 JAMA 1418 (1995). The
potential bias of this source is considerable, though the points raised against the previous study are noteworthy.
74See Id.
75See Prothro, supra note 5 at 69.
76See “Wikipedia, the Free Encyclopedia – LD50,” available at http://en.wikipedia.org/wiki/LD50.
77See Id.
78See Prothro, supra note 5 at 69. See also “Wikipedia,” supra note 6.
13This type of fatality is extremely unlikely. Besides the fact that enormous quantities of caﬀeine are required
to reach fatal toxic levels, and such quantities must be ingested rapidly, the most commonly used caﬀeine-
containing substances such as coﬀee and soda would cause signiﬁcant gastric irritation, acid secretion, nausea,
and vomiting, irrespective of their caﬀeine content if ingested at those volumes.79 More importantly, these
eﬀects would likely take place long before the fatal toxicity could be reached.80
Even in non-lethal doses, large quantities of caﬀeine can cause potentially signiﬁcant health problems, includ-
ing conditions that may be considered “long-term poisoning.”81 According to an article in the Journal of
Forensic Science, a one-thousand milligram dose of caﬀeine, or one-tenth of the LD50, has been known to
cause convulsions, uncomfortably rapid breathing, tachycardia, hyperglycemia, and ketonuria.82 Continual
caﬀeine intake at lower levels can also cause borderline toxic responses – restlessness, disturbed sleep, irri-
tability, muscle tension, cardiac arrhythmia, persistent nervousness, or sporadic reactions similar to anxiety
attacks.83
Incidences of signiﬁcant or borderline toxic responses to caﬀeine are not frequent enough to be considered
problematic84; however, there are “rare persons who are so sensitive to caﬀeine that even a single cup of
coﬀee will cause a response bordering on the toxic.”85 Certain groups are also more generally susceptible
to the eﬀects of caﬀeine; because of its correlation with body weight, children are often disproportionately
79See Goodman & Gilman, supra note 4 at 678.
80See Id.: (“It has been long known <and perhaps forgotten> that beverages made from roasted grain containing no caﬀeine
stimulate acid secretion in human beings as much as does coﬀee. Decaﬀeinated coﬀee is only slightly less potent than the
natural product in enhancing the secretion of gastrin and acid, and both are about twice as eﬀective as is an equivalent amount
of caﬀeine”).
81See Id.: (“Overindulgence in xanthine beverages may lead to a condition that might be considered one of long-term
poisoning”).
82P.L. Morrow, “Caﬀeine Toxicity: A Case of Child Abuse by Drug Ingestion,” 32 J. Forensic Sci. 1801, 1803 (1987).
83See Prothro, supra note 5 at 70. See generally Brain, supra note 14. See generally Goodman & Gilman, supra note 4.
84See generally “Caﬀeine Health – What to Worry About,” available at http://www.coﬀeeforums.com.
85See Goodman & Gilman, supra note 4 at 678.
14aﬀected by smaller doses of caﬀeine.86 Similarly, some elderly people have been known to experience a
disproportionate interruption of the sleep cycle simply from ingesting caﬀeinated medications.87
Pregnant women are also generally advised to avoid caﬀeine, for a variety of reasons. Though it has not been
linked to “pre-term labor, low birth weight, or birth defects,” physicians generally suggest that pregnant
women abstain from caﬀeine intake due to the suspicion of an increased likelihood for miscarriage and intra-
uterine growth retardation.88 Because of the potential for caﬀeine transmission through breast milk, women
who are planning to breast feed a child are similarly encouraged to avoid caﬀeine.89
Sleep deprivation caused by caﬀeine is worthy of separate mention. While the obvious “wake up” beneﬁt of a
morning cup of coﬀee is well known, the cost associated with this beneﬁt is the potential for delayed negative
eﬀect on adenosine absorption.90 Adenosine is critical to deep, restful sleep; the later in the day an individual
86Prothro, supra note 5 at 70: (“And children often display symptoms of attention deﬁcit / hyperactivity disorder when they
consume caﬀeine.... Because the potency of caﬀeine on a human body depends on the body’s weight, children are far more
sensitive to caﬀeine than adults – a single soft drink <containing 30-46 mg of caﬀeine> aﬀects a young child the way two cups
of coﬀee <130-230 mg of caﬀeine> aﬀect an adult”).
87Id.
88Id., citing Isabel Fortier et al., “Relation of Caﬀeine Intake During Pregnancy to Intrauterine Growth Retardation and
Preterm Birth,” 137 Am. J. Epidemiology 931, 931-40 (1993).
89Id. According to some sources, caﬀeine may correlate with greater diﬃculty among women in conceiving children, though
further exploration of this linkage is required; See e.g. Doheny, supra note 60. But see “Caﬀeine CERHR Study,” (Aug. 2003),
available at http://cerhr.niehs.nih.gov/genpub/topics/caﬀeine-ccae.html, stating that (“numerous studies have examined the
eﬀects of caﬀeine intake on fertility and pregnancy. Most studies found that moderate caﬀeine intake does not aﬀect fertility or
increase the chance of having a miscarriage or a baby with birth defects; some studies did ﬁnd a relationship between caﬀeine
intake and fertility or miscarriages. However, most of those studies were judged to be inadequate because they did not consider
other lifestyle factors that could contribute to infertility or miscarriages. The Organization of Teratology Information Services
(OTIS) stated that there is no evidence that caﬀeine causes birth defects in humans. Groups such as OTIS and Motherisk agree
that low caﬀeine intake (<150 mg/day or 1-1/2 cups of coﬀee) will not likely increase a woman’s chance of having a miscarriage
or a low birth weight baby. Motherisk recommends that caﬀeine intake by pregnant women not exceed 150 mg/day whereas
OTIS stated that moderate caﬀeine intake of 300 mg/day (equivalent to about 3 cups of coﬀee) does not seem to reduce fertility
in women or increase the chances of having a child with birth defects or other problems. Caﬀeine can enter breast milk, and
high amounts can cause the baby to become wakeful and agitated. The American Academy of Pediatrics recommends that
nursing women limit caﬀeine intake, but states that no harm is likely to occur in a nursing child whose mother drinks one cup
of coﬀee a day. OTIS recommends that pregnant and nursing women drink plenty of water, milk, and juice and not substitute
those ﬂuids with caﬀeinated beverages”).
90See Brain, supra note 14.
15consumes caﬀeine, the longer the adenosine replacement will take place and conﬂict with ordinary restful
sleep cycles.91 For example, using caﬀeine’s estimated three and a half hour half-life, a single one-hundred
milligram dose of the drug taken at four o’clock p.m. will be at half strength at seven thirty. In general,
more caﬀeine consumed later in the day will be increasingly likely to cause sleep disturbances; this further
fuels the need for caﬀeine to facilitate the body’s awakening the following morning.92
Caﬀeine also poses a potential problem when considered in concert with other prescription drug therapies
and physician diagnoses. Goodman & Gilman’s chapter on methylxanthines notes
the xanthine beverages present a medical problem in that a large fraction of the population
consumes enough caﬀeine to produce substantial eﬀects on a number of organ systems.
Hence, the physician should give due consideration to the possible contribution of caﬀeine
to the presenting signs and symptoms of patients, as well as to its potential interaction with
any contemplated therapeutic regimen.93
Considering its known stimulating eﬀects, those patients who could frustrate existing medical conditions
through its use should avoid caﬀeine intake. For example, people with abnormal heart function, including
tachycardia and arrhythmia, should avoid caﬀeine because it could unnecessarily stimulate cardiac function.94
Similarly, people with existing sleep disorders should avoid the interruptive eﬀects of adenosine replacement.
Finally, patients with gastrointestinal dysfunction of any kind, including gastro-esophageal reﬂux disease
and peptic ulcers, should limit intake or omit caﬀeine entirely from daily consumption.95
F. Caﬀeine: The Problem of Disputed Science
91See Id.
92See Id.
94See Prothro, supra note 5 at 71.
95See generally Goodman & Gilman, supra note 4.
16Though caﬀeine is generally considered to be a safe product provided it is taken in small quantities, it
may still be considered a poisonous substance regardless of the amount ingested.96 Some sources are more
concerned about its ready availability to the public, fearing untold long-term risk of overuse.97 Many sources,
however, defend the use of caﬀeine, claiming that much of the previous study research implicating it in a
variety of health problems was poorly done or at best inconclusive.98
Several of the presumed linkages between caﬀeine use and signiﬁcant health problems have recently been
debunked as a result of new laboratory information.99 For example, a famous 1980 study posited a link
between caﬀeine use and ﬁbrocystic breast disease; the correlation was later summarily dismissed.100
The supposed connection was suggested by a surgeon’s study, in 1980, which relied on
interviews with a small number of women but included no objective examination of their
breast tissue. Since then, the few well-designed studies have found no association.101
Medical studies of caﬀeine continue to evolve and conﬂict; this makes deﬁnitive causal connections between
caﬀeine and individual health concerns increasingly more diﬃcult to establish.
A clear example of the conﬂicts among caﬀeine data involves the perceived correlation between caﬀeine use
and bone fragility, particularly in post-menopausal women. According to an older Harvard-based study of
more than one-hundred-thousand nurses, caﬀeine intake has a negative correlation with the body’s ability
to retain calcium, potentially altering bone density and increasing the likelihood of bone fracture and osteo-
porosis.102 However, a recent evaluation of bone density data refutes the presumed linkage between caﬀeine
use and calcium retention, and suggests that there is no veriﬁable independent link between bone fragility
96See “Caﬀeine Health,” supra note 84.
97See Prothro, supra note 5 at 71.
98See generally Adamson & Roberts, supra note 73.
99See generally “Caﬀeine Health,” supra note 84.
100See “Questions and Answers; Caﬀeine and Breast Disease,” Consumer Rep., July 1995, at 493.
102Jane Brody, “Caﬀeine, The Doctor’s Report,” Dallas Morning News, Sept. 25, 1995, at 3C.
17and the use of caﬀeine-containing substances.103 Therefore signiﬁcant concern about the issue is thought to
be unfounded.104
Elevated risk of heart disease is a second important example of conﬂicting data in caﬀeine studies, especially
since heart disease is now the largest cause of death in the United States.105 While “some studies linked
caﬀeine consumption to an increased risk of heart disease, particularly in men,”106 more recent research
reﬂects no such negative correlation between caﬀeine intake and heart disease.107
Cardiovascular disease (CVD)...has been the subject of extensive medical and scientiﬁc
research for several decades. While researchers have diﬀered in their conclusions over time,
new evidence in 1999 strongly indicates that consumption of coﬀee and caﬀeine does not
contribute to CVD, ﬁnding neither caﬀeinated nor decaﬀeinated coﬀee associated with the
risk of stroke – even for those drinking more than four cups of coﬀee a day.108
A 1994 review of the relevant medical literature similarly concluded that, “[t]he largest and better studies
suggest that coﬀee is not a major risk factor for coronary disease.”109 Numerous other studies reﬂecting
similar ﬁndings have been done in the past ﬁfteen years, indicating that the espoused link between caﬀeine
consumption and heart disease is probably spurious.110
103See “Coﬀee, Caﬀeine, and Osteoporosis,” The Coﬀee Science Information Centre, available at
http://www.cosic.org/mainissues/article/11: (“Earlier papers have suggested that caﬀeine may aﬀect bone health, though
these researchers stress that uncontrolled confounding factors may be responsible. The vast majority of recently published
studies do not suggest caﬀeine as an independent risk factor for osteoporosis”).
104See Id.
105See “Understanding Coﬀee, Caﬀeine, and Cardiovascular Disease,” Coﬀee Science Source, available at
http://www.coﬀeescience.org/heart.html: (“Cardiovascular disease (CVD), coronary heart disease, is the number one
cause of death in America”).
106Prothro, supra note 5, citing Dag S. Thelle et al., “Does Coﬀee Raise Serum Cholesterol Level,” 308 New Eng. J. Med.
1454-57 (1983); Andrea Z. LaCroix et al., “Coﬀee Consumption and the Incidence of Coronary Heart Disease,” 315 New Eng.
J. Med. 977-82 (1986); Lynn Rosenberg et al., “Coﬀee Drinking and Nonfatal Myocardial Infarction in Men Under 55 Years of
Age,” 128 Am. J. Epidemiology 570-78 (1988); Lynn Rosenberg et al., “Coﬀee Drinking and Nonfatal Myocardial Infarction
in Young Women: An Update,” 126 Am. J. Epidemiology 147-49 (1987).
107See “Understanding Coﬀee, Caﬀeine, and Cardiovascular Disease,” supra note 105.
109See Warren G. Thompson, “Coﬀee: Brew or Bane?” 308 Am. J. Med. Sci. 349, 349-57 (1994).
110See e.g. Walter C. Willet et al., “Coﬀee Consumption and Coronary Heart Disease in Women,” 275 JAMA 458, 458-62
18At one time, caﬀeine was erroneously thought to be potentially carcinogenic; due to its diuretic properties,
caﬀeine was believed to be linked to increased likelihood of bladder cancer.111 However, a new wealth of
study data now not only suggests that caﬀeine has no links to the promotion of cancer growths, the data
also shows that caﬀeine-containing substances may actually combat certain types of cancer formation.112
Though more information is needed to link caﬀeine to combating cancer, suﬃcient data exists to remove
caﬀeine from consideration as a carcinogen.113
Several other presumed health linkages of lesser severity have also recently been called into question. For
example, caﬀeine intake was once thought to be highly correlated with spikes in blood pressure, elevated
serum cholesterol levels, and the exacerbation of existing cardiac conditions, including arrhythmia.114 New
(1996); utilizing a data set including 85,000 women over a ten year period, and adjusting for known risk factor variables, the
authors found no link whatsoever between risk of coronary heart disease and coﬀee consumption in women, even for women
ingesting more than six cups of coﬀee daily. See also Diederick E. Grobbee et al., “Coﬀee, Caﬀeine and Cardiovascular Disease
in Men,” 323 New Eng. J. Med. 1026, 1026-32 (1990); ﬁnding no link between heart disease and caﬀeine consumption in a
sample of over 45,000 men, whose daily caﬀeine intake included four or more cups of coﬀee.
111See e.g. Jean Carper, “Caﬀeine: The Bitter Truth,” USA Weekend Magazine, available at
http://www.usaweekend.com/99 issues/991003/991003eatsmart.html: (“[t]here’s little evidence that caﬀeine promotes
cancer, except possibly bladder cancer”).
112See e.g. “Other Questions About Coﬀee and Health – Coﬀee and Caﬀeine Content,” available at
http://www.coﬀeescience.org/other.html: (“Decades of research and centuries of human consumption conﬁrm the safety of
coﬀee and caﬀeine.... In fact, recent scientiﬁc research carried out at the Mayo Clinic, Harvard School of Public Health, U.S.
Veterans Administration and other medical centers show that coﬀee is not only safe but beneﬁcial – drinking from 2 to 4
cups of coﬀee a day may lower the risk of colon cancer (25%), gallstones (45%), cirrhosis of the liver (80%), and Parkinson’s
Disease (50-80%), among other diseases”). See also Giovannucci, “Meta-Analysis of Coﬀee Consumption and Risk of Colorectal
Cancer,” 147 Am. J. Epidemiology 1043, 1043-1052 (June 1998); consolidating seventeen separate studies on colorectal cancer
and caﬀeine consumption, and ﬁnding a 24% reduced risk among consumers of four or more cups of coﬀee per day. See also
“Caﬀeine Clue to Fighting Cancer,” BBC News World Edition, available at http://news.bbc.co.uk/2/hi/health/2207153.stm;
discussing a University College London study which found that: (“Chocolate, cola and coﬀee could form the basis of new anti-
cancer drugs, scientists believe. Researchers in the UK have found that caﬀeine and theophylline may be eﬀective in ﬁghting
cancer tumours [sic]”). See also Carper, supra note 111: (“Recent Japanese research suggests that caﬀeine alters hormones in
ways that may reduce the odds of breast cancer. New research in Switzerland has found coﬀee drinkers have a 27% lower risk
of developing colon cancer. A study at Harvard suggested four to ﬁve cups of coﬀee a day reduced the risk of colorectal cancer
by 24%”).
113See “Coﬀee, Caﬀeine, and Cancer,” The Coﬀee Science Information Centre, available at
http://www.cosic.org/mainissues/article/14/: (“In 1990, IARC, the International Agency for Research on Cancer held
a monograph on Coﬀee, Caﬀeine, Tea, and Mate.... Coﬀee was cleared in all areas with the exception of bladder cancer
where there was insuﬃcient evidence available at that time. Several studies since have clearly shown no linkage between
coﬀee consumption and bladder cancer”). See also “Food, Nutrition and the Prevention of Cancer: A Global Perspective,”
American Institute for Cancer Research, (1997): (“Most evidence suggests that regular consumption of coﬀee and/or tea has
no signiﬁcant relationship with the risk of cancer at any site”).
114See “Understanding Coﬀee, Caﬀeine, and Cardiovascular Disease,” supra note 105.
19data suggests that each of these health linkages is suspect. For instance, while caﬀeine certainly does correlate
to a short-term spike in blood pressure to a xanthine-na¨ ıve body, such eﬀect is “transient,” and “[n]o changes
in blood pressure appear to occur in regular users of caﬀeine.”115 Furthermore, serum lipid and cholesterol
levels do not show any increase in coﬀee prepared “by drip machines and percolators.”116
Admittedly, physicians generally remain cautious and encourage patients suﬀering from mild cardiac dys-
function to avoid excessive caﬀeine intake; there is little incentive not to follow this precautionary measure.117
However, a 1991 article reviewing medical studies on coﬀee and caﬀeine in conjunction with arrhythmias
and tachycardia found that a daily dose of ﬁve-hundred milligrams of caﬀeine, or the rough equivalent of ﬁve
standard cups of coﬀee, “does not increase the frequency or severity of cardiac arrhythmias or ventricular
tachycardia in healthy people or those with CVD.”118 Thus, even health problems once considered to be
obviously correlated with caﬀeine use are now being substantially called into question, or dismissed entirely.
G. Caﬀeine Alternatives: Balancing Costs and Beneﬁts
The long-popular American slogan, “everything in moderation,” applies just as well to caﬀeine as it does
to almost any other food, drug, or activity. In very large doses, caﬀeine is admittedly a poison. In small
doses and in rare circumstances, caﬀeine can potentially cause health problems, though the scope of these
problems and the level of medical concern both continue to change with new research developments. This
115See Id., citing Annette Bak and Diederick Grobbee, “Caﬀeine, Blood Pressure and Serum Lipids,” 53 Am. J. Clinical
Nutrition 971, 971-974 (1991).
116Id., referring to a Scandinavian study that found small increases in serum lipids only through preparation of unﬁltered
boiled coﬀee – (“a process little used in the U.S.”).
117See generally Goodman & Gilman, supra note 4.
118See Id., citing M. G. Meyers, “Caﬀeine and Cardiac Arrhythmias,” 114 Annals of Internal Med. 147, 147-150 (1991).
20is, practically speaking, no diﬀerent from any other food or drug item in daily life; too much of virtually
anything can be toxic. However, even considering its addictiveness, caﬀeine is seemingly harmless the vast
majority of the time, for the vast majority of people concerned.119
Even still, the market has produced alternatives to, and substitutes for, caﬀeine. In the early 1980s, after
the market produced a “health craze,” soda companies began producing numerous decaﬀeinated colas; these
sodas continue to be widely available today.120 Nowadays, decaﬀeinated options are made available for
consumers virtually everywhere teas and coﬀees are sold. For those consumers concerned with caﬀeine content
in over-the-counter pain relievers, numerous replacement drugs do not have caﬀeine as an ingredient.121
One particular new source of concern is the American public’s recent infatuation with herbal remedies
and supplements; many stimulants, including Ma Huang (Ephedra sunensis), Ginseng (Panax quinque-
folium), and Guarana (Paullinia cupana), have become exceedingly common in the market, both as over-
the-counter supplements and in food and beverage products, particularly energy drinks.122 Besides the short
and long-term health eﬀects speciﬁc to each natural substance, some products like Ma Huang are variations
of Ephedrine (recently pulled from the market by the FDA),123 and others contain large quantities of caﬀeine
and synthetic caﬀeine substitutes.124
119See generally Thompson, supra note 109. See generally Goodman & Gilman, supra note 4.
120See Prothro, supra note 5 at 74, citing Toni Minarich & Janet Havter, “Elephantine Enlightenment,” Beverage World, July
1995, at 66.
121See e.g. “Anacin” and “Excedrin” versus other common pain relievers such as ibuprofen.
122A search, available at http://www.google.com, for the combined terms “Buy”, “Ginseng”, “Guarana”, and “Ma Huang”
yielded more than seven thousand web pages, the vast majority of which were purchasing sites.
123See “Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited,” available at
http://www/fda/gov/oc/initiatives/ephedra/february2004/: (“On April 12, 2004, a ﬁnal rule went into eﬀect prohibit-
ing the sale of dietary supplements containing ephedrine alkaloids <ephedra>. Ephedra, also called Ma Huang, is a naturally
occurring substance derived from plants. Its principal active ingredient is ephedrine, which when chemically synthesized is
regulated as a drug. In recent years ephedra products have been extensively promoted to aid weight loss, enhance sports
performance, and increase energy. But FDA has determined that ephedra presents an unreasonable risk of illness or injury. It
has been linked to signiﬁcant adverse health eﬀects, including heart attack and stroke”).
124See e.g. “Body and Fitness,” available at http://www.bodyandﬁtness.com/products/health/energy.htm; one particular
proprietary energy supplement sold at this source, a capsule called “Super Enermax,” contains the following ingredients: 200mg
guarana, 200mg yerba mate, 100mg green tea, 50mg ginseng, 50mg kola extract, and 50mg rhodiola. Most of these additives
contain some portion of natural caﬀeine, particularly guarana (half of the 200mg is caﬀeine), and yerba mate (a dried herb
containing even higher levels of natural caﬀeine). Therefore, though the product may contain a wide variety of “natural energy-
21The FDA faces a separate regulatory challenge in dealing with these products, many of which do not present
the natural caﬀeine content of the product’s ingredients for greater consumer awareness.125 Fortunately, due
to much of the recent study data’s suggestion that caﬀeine is not nearly as dangerous as once thought,126
the proliferation of caﬀeinated substances in the marketplace is not of great concern; individual consumers
can readily avoid consuming toxic quantities of caﬀeine through moderation, with little eﬀort.127
III. Caﬀeine and the FDA: The Regulatory Framework
The United States maintains one of the world’s safest supplies of food and drugs, thanks in large measure to
the “interlocking monitoring system that watches over food production and distribution.”128 The Food and
Drug Administration (FDA) is one of the focal points of this monitoring system, and has broad responsibilities
regarding the oversight of foods, drugs, and other medical products.129 The main regulatory authority for
the FDA’s work “originated with the Federal Food, Drug, and Cosmetic Act of 1938” (FDCA), though
the powers and responsibilities of the FDA have been updated through legislation several times since its
passage.130 The FDA “regulates over $1 trillion worth of products, which account for 25 cents of every
boosting ingredients,” the total caﬀeine content of a pill this size is several ordinary doses, and likely accounts for the vast
majority of the energy boost that a consumer will experience.
125For example, consumers may be unaware that guarana and similar “natural” ingredients contain caﬀeine naturally.
126See generally “Caﬀeine: The Problem of Disputed Science” section above.
127See Prothro, supra note 5 at 75: (“As with much else in our food and drug supply, moderation is the answer and should
be the message conveyed by the FDA”).
128See “Food Safety: A Team Approach,” FDA Backgrounder, Sep. 24, 1998, available at
http://www.fda.gov/opacom/backgrounders/foodteam.html.
129Sharon Wyatt Moore, “An Overview of Drug Development in the United States and Current Challenges,” 96 Southern
Med. J. 12, 1244 (Dec. 2003). See also “Food Safety,” supra note 128, which outlines the overall U.S. government regulatory
structure with regard to control over the food and drug supply, including the interlocking roles of the U.S. Department of
Health and Human Services, the U.S. Department of Agriculture, the U.S. Environmental Protection Agency, and several other
agencies.
130Id. at 1245.
22dollar spent annually by American consumers.”131
A. Caﬀeine and the FDA: A Brief History of Dual Regulation
In general, FDA regulation requires that new drugs demonstrate that they are safe and eﬃcacious for
consumer use before companies market them to the public.132 By statute, a drug is deﬁned as any article
“intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.”133 FDA regulation
also ensures that the foods consumed by Americans on a daily basis are generally “safe and wholesome,” and
that all of the food and drug products available to the public are “labeled truthfully with the information that
people need to use them properly.”134 Statute deﬁnes food as any article “used for food or drink”;135 courts
have further deﬁned food in terms of “its function as food, rather than in terms of its source, biochemical
131“The Food and Drug Administration: An Overview,” available at http://www.cfsan.fda.gov/fdaoview.html.
See also “Health Information Resource Database,” National Health Information Center, available at
http://health.nih.gov/search results.asp; explaining the broad goals of the FDA: (“The mission of the U.S. Food and
Drug Administration (FDA) is to: promote the public health by promptly and eﬃciently reviewing clinical research and taking
appropriate action on the marketing of regulated products in a timely manner; with respect to such products, protect the
public health by ensuring that foods are safe, wholesome, sanitary, and properly labeled; human and veterinary drugs are
safe and eﬀective; there is reasonable assurance of the safety and eﬀectiveness of devices intended for human use; cosmetics
are safe and properly labeled, and; public health and safety are protected from electronic product radiation; participate
through appropriate processes with representatives of other countries to reduce the burden of regulation, harmonize regulatory
requirements, and achieve appropriate reciprocal arrangements; and, as determined to be appropriate by the Secretary, carry
out paragraphs (1) through (3) of The FDA Modernization Act of 1997 (PL 105-115) in consultation with experts in science,
medicine, and public health, and in cooperation with consumers, users, manufacturers, importers, packers, distributors and
retailers of regulated products”).
132See Moore, supra note 129. A brief description of the evolution and scope of FDA authority follows: (“Although earlier drug
legislation existed, this Act established the authority of the FDA to require that new drugs demonstrate safety before they could
be marketed. The Kefauver-Harris Drug Amendments, passed in 1962, then required new drugs to demonstrate eﬃcacy before
marketing. In the 1970s, the FDA’s scope enlarged when the Public Health Service Bureau of Radiologic Health transferred to
the FDA in 1971, the regulation of biologics transferred to the FDA from the National Institutes of Health (NIH) in 1972, and
Medical Device Amendments were passed in 1976, establishing new regulatory procedures for medical device manufacturers.
The Food and Drug Administration Act of 1988 oﬃcially established the FDA as an agency within the Department of Health
and Human Services and noted that the President appoints the Commissioner of the FDA. This was followed by the Food and
Drug Administration Modernization Act of 1997 (FDAMA), providing the most wide-ranging reforms in the FDA since 1938.
The purposes of the FDAMA legislation included accelerated review of drugs and medical devices and regulation of advertising
of unapproved uses of approved medical products”). See also http://www.fda.gov, for more general information regarding the
FDA’s regulatory purview and history.
13321 U.S.C. 321(g)(1) (1994). The statute further includes any article (“other than food intended to aﬀect the structure or
any function of the body”).
134See “The Food and Drug Administration: An Overview,” supra note 131.
13521 U.S.C. 321(f) (1994).
23composition or ingestibility.”136
Due to its content in such a wide variety of products, caﬀeine poses interesting regulatory challenges for the
FDA, which “regulates caﬀeine extensively as a drug and a food.”137 This kind of dual regulation is not at
all uncommon; due to fact that the FDCA “has not been interpreted to require the deﬁnitions of food and
drug to be mutually exclusive,”138 the FDA instead tends to regulate substances that appear both in foods
and drugs based on the advertising of the products.139
At ﬁrst glance, it may seem odd that the same substance can be regulated ‘inconsistently,’
sometimes as a drug and other times as a food. For example, it may seem odd that chewing
gum can be a drug simply because it contains caﬀeine and is advertised as a ‘natural energy
booster.’ But this oddity is not limited to caﬀeine....140
Moreover, deﬁnitions of articles adopted by the FDA are granted “substantial deference by courts.”141
Several factors generally apply to the FDA’s classiﬁcation of a caﬀeine-containing product as either a food
or a drug, the most important of which are: (1) whether the product is intended to be used for the diagnosis
or treatment of disease; (2) whether it is intended to aﬀect the body’s structure or its function; and most
importantly - (3) the speciﬁc intent of the vendor.142 Vendor intent “may be derived or inferred” based
on the product’s “labeling, promotional material, advertising, and any other relevant source.”143 Another
136See Prothro, supra note 5 at 76, citing Nutrilab, Inc. v. Schweiker, 713 F.2d 335, 337 (7th Cir. 1983).
137See Id. at 75.
138See Id.
139See S. Rep. No. 74-361, at 4 (1935): (“If it is sold to be used both as a food and for the prevention or treatment of disease
it would satisfy both deﬁnitions and be subject to the substantive requirements for both”). Cited in Prothro, supra note 5 at
75.
141See American Health Prods. Co. v. Hayes, 574 F. Supp. 1498, 1501 (S.D.N.Y. 1983), aﬀ’d per curium, 744 F.2d 912 (2d
Cir. 1984). See also United States v. Neptone, holding (“the determination that Neptone is a drug rests entirely on the pattern
of promotion used by claimant in the several years immediately preceding the instant seizure”).
142See National Nutritional Foods Ass’n v. Mathews, 557 F.2d 325, 333 (2d Cir. 1977): (“[t]he vendor’s intent in selling the
product to the public is the key element in this statutory deﬁnition”).
143Id. at 334. See also Prothro, supra note 5 at 76-77: (“Thus, if one markets a caﬀeinated soft drink as just a soft drink, it
will likely be regulated as a food. But if one markets it as a soft drink to help maintain ‘blood energy, muscular activity, sound
teeth and gums,’ it will likely be regulated as a drug and require FDA pre-market approval”), ref. United States v. Kordel, 164
F.2d 913, 916 (7th Cir. 1947), aﬀ’d, 335 U.S. 345 (1948); in which the “Kola” product sarsaparilla was declared a mislabeled
24common factor in the FDA’s calculus is whether or not the product is recognized in “oﬃcial compendia”;144
however, while the courts generally grant extraordinary deference to the FDA’s classiﬁcation decisions, the
courts are not in universal agreement about the application of this last factor.145
B. Caﬀeine and the FDA I: Regulation as a Food
The FDA’s choice in regulating caﬀeine either as a food or as a drug has important ramiﬁcations for the
leniency or severity of the regulation imposed.146 In general, the FDA’s caﬀeine regulation is much less
severe when applied to foods rather than drugs, though the level of leniency varies depending on whether
caﬀeine is added to foods or occurs naturally.147 Manufacturers of foods, dietary supplements, soft drinks,
and many other ingestible consumer products generally prefer classiﬁcation of their products as foods rather
than as drugs, in order to beneﬁt from the leniency of food regulation.148 A spokesman for the FDA noted
that
diﬀerent regulations apply to drugs and foods. These diﬀerences include the labeling of the
product, requirements for premarketing approval, practices required during manufacturing,
the records that must be maintained during production and manufacturing, and the way in
which the substance is dispensed.149
drug as opposed to a food because it made health claims like a drug.
144See Prothro, supra note 5 at 76.
145See e.g. Mathews, supra note 142 at 337: (“the mere inclusion in the USP (United States Pharmacopeia) and the NF
(National Formulary) is an insuﬃcient basis for drug classiﬁcation”). But see United States v. Beuthanasia-D Regular, [1979
Transfer Binder] Food Drug Cosm. L. Rep. P38265 (D. Neb. 1979); holding that such inclusion is conclusive evidence of drug
status. Cited in Prothro, supra note 5 at note 80.
146See generally http://www.fda.gov, for a more complete description of the diﬀerences between food regulation and drug
regulation.
147See Prothro, supra note 5 at 80. See also Prothro, supra note 5 at note 106: (“In coﬀee, tea and chocolate, for instance,
caﬀeine occurs naturally and is nonadded. In soft drinks, however, caﬀeine is a food additive; only 5% of the caﬀeine present
is naturally occurring <from the Kola nut>”).
148See John Vanderveen, “Regulation of Amino Acids and Other Dietary Components Associated with Enhanced Physical
Performance,” Report from the Director of the FDA’s Oﬃce of Plant and Dairy Foods and Beverages, Nov. 1992, available at
http://www.books.nap.edu/books/030905088X/html/461.html.
25With respect to each of the factors above, compliance with food regulation is both easier and less costly than
compliance with corresponding drug regulation.150
Much of the FDA’s past discussion of caﬀeine-containing foods revolved around the GRAS, or “generally
regarded as safe,” status of caﬀeine. Under statute, the FDA recognizes a wide variety of substances that
satisfy GRAS; these substances include salt, pepper, vinegar, monosodium glutamate, common essential oils,
spices, natural extracts, and artiﬁcial colors and ﬂavors.151 Caﬀeine as added to cola products has been a
component of the GRAS list since 1961;152 its use continues to be generally regarded as safe subject to a
drug tolerance requirement of 0.02 percent by weight, and provided that it is added to sodas “in accordance
with good manufacturing practice.”153
The adherence to “good manufacturing practice” means that: (1) “the quantity of a substance added to
food does not exceed the amount reasonably required to accomplish its intended physical, nutritional, or
other technical eﬀect in food”; (2) “the quantity...that becomes a component of food” through processing
or manufacturing “and which is not intended to accomplish any physical or other technical eﬀect in the food
itself, shall be reduced to the extent reasonably possible”; and (3) “the substance is of appropriate food
grade and is prepared and handled as a food ingredient.”154
By the FDA’s estimation, soda manufacturers have thus far complied with these manufacturing requirements;
therefore, caﬀeine is exempt from the provisions of the 1958 Food Additives Amendment and its successor
150See generally Moore, supra note 129, for a more comprehensive analysis of the costs associated with drug regulation
compliance.
151See 21 C.F.R. 182, at 456 (2003), available at http://www.cfsan.fda.gov/∼lrd/FCF182.html.
152See 26 Fed. Reg. 938 (1961).
153See 21 C.F.R. 182, at 462 – “Subpart B—Multiple Purpose GRAS Food Substances, Sec. 182.1180,” available at
http://www.cfsan.fda.gov/∼lrd/FCF182.html.
15421 C.F.R. 182, supra note 151 at 456. This regulation does bear the caveat that (“the inclusion of substances in the list of
nutrients does not constitute a ﬁnding on the part of the Department that the substance is useful as a supplement to the diet
for humans”).
26provisions through retention of GRAS status.155 In the 1980s, however, GRAS status was somewhat in
doubt:
In 1980, the FDA proposed to delete caﬀeine from the GRAS list, to declare that no prior
“sanction” existed, and to restrict the use of caﬀeine in food to its 1980 levels until further
studies could be conducted. It was prompted to issue the proposal by animal test results
that suggested a link between caﬀeine and birth defects and raised concerns about caﬀeine’s
potential teratogenecity.156
In 1987, following a ﬁnding that a 0.02 percent by weight requirement would be suﬃcient to protect the
public from injury,157 the FDA took strides in the opposite direction and instead proposed to grant a “prior
exception” for caﬀeine as a soft drink additive.158 To date, however, the 1987 proposal has not been acted
upon, and caﬀeine remains on the GRAS list.159
Aside from GRAS status, the most obvious aspect of caﬀeinated food regulation is the requirement that
caﬀeine appear in the list of ingredients when it is used as a food additive.160 Interestingly, this regulation
tends to apply primarily to soft drinks, and is not required in products that have natural caﬀeine content but
no added caﬀeine. Moreover, the FDA does not require speciﬁc disclosure of the quantity of caﬀeine in food
products, though some sources supply such information voluntarily.161 While natural sources of caﬀeine,
including coﬀees, teas, and chocolates go largely unregulated and unnoticed by the FDA,162 the same cannot
155See 21 U.S.C. 348 (1972), for a more complete listing of the requirements of the Food Additives Amendments.
157See 52 Fed. Reg. 18,923, 18,925 (1987).
158See 52 Fed. Reg. 18,923 (1987).
159See 21 C.F.R. 182, supra note 153 at 462. See also Prothro, supra note 5 at 81.
160See “How Are Additives Approved for Use in Foods?” Food Additives FDA/IFIC Brochure (Jan. 1992), available at
http://www.cfsan.fda.gov/∼lrd/foodaddi.html.
161For example, the list of ingredients on virtually any caﬀeinated soda product contains caﬀeine as a single ingredient in the
list, along with all the artiﬁcial ﬂavors, colors, and other additives used to preserve the product. However, information about the
speciﬁc quantity of caﬀeine in popular products is readily available on the internet. See e.g. “Caﬀeine Content of Soft Drinks,”
National Soft Drink Association (Oct. 2003), available at http://nsda.org/WhatsIn/caﬀeinecontent.html. See also “Caﬀeine
Content of Foods and Drugs,” CSPI Press Releases (July 1997), available at http://www.cspinet.org/new/cafchart.htm, for a
more comprehensive listing of caﬀeine content in common products.
162See Prothro, supra note 5 at 82.
27be said for caﬀeine-containing substances regulated as drugs.
C. Caﬀeine and the FDA II: Regulation as a Drug
Whether used as one of the world’s ﬁrst all natural energy drinks for shepherds and nomads, a religious
zealot’s device for maintaining all-night prayer, a sixteenth-century European panacea, or a modern miracle
“wake-up” drug, caﬀeine has been used throughout the centuries for its stimulant eﬀect.163 In the United
States today, however, pharmaceutical companies, food and beverage makers, and particularly over-the-
counter producers of “energy products” are all subject to a wide variety of regulation, and cannot therefore
market caﬀeine with reckless abandon.164
The FDA strictly controls the drug market and requires extensive showings of safety and
eﬀectiveness before it will allow caﬀeine (or any other drug) to be used as a drug ingredient.
It does so ‘to protect consumers and enable them to know what they’re buying.’165
In order to regulate the behavior of American drug companies, the FDA publishes numerous documents
involving product requirements and instructions; the two main types of documents are Regulations and
Guidances.166 The two document types diﬀer in important ways: “Regulations are legally binding require-
ments found in Title 21 of the Code of Federal Regulations and must be followed,” whereas Guidances
“represent the FDA’s current thinking and recommendations” but are nonbinding and subordinate to Reg-
ulations.167 In order for any drug to be introduced into the market, it must conform to all codiﬁed FDA
163See “History of Caﬀeine,” available at http://web1.caryacademy.org/chemistry/rushin/StudentProjects/CompoundWebSites/1998/Caﬀeine/history of caﬀeine.htm.
See also Goodman & Gilman, supra note 4 at 672.
164See Prothro, supra note 5 at 77.
166See Moore, supra note 129 at 1245.
167Id. Guidances also (“usually contain greater detail about speciﬁed topics and can be updated more easily”).
28regulations regarding safety and eﬀectiveness.168
Once a company has submitted a drug for approval, the FDA will then review the company’s application
and issue a monograph classifying the drug.169 A drug must receive a Category I monograph from the FDA
before it can be marketed to the public; this means the FDA views the new product as safe, eﬀective, and
not misbranded.170 A Category II classiﬁcation means that the FDA must withhold market approval; by
contrast, a Category III classiﬁcation requires the petitioning company to obtain more data and submit for
further FDA scrutiny prior to a ﬁnal classiﬁcation as either a Category I or Category II drug.171
Since technical information is essential to the process of drug approval, the FDA relies heavily on the
independent expertise of advisory panels and committees.172 The general role of an advisory panel is “to
provide independent advice that will contribute to the quality of the agency’s regulatory decision-making
and lend credibility to the product review process.”173 This helps the FDA make better-informed decisions,
while giving outside ﬁeld experts the opportunity “to comment on whether adequate data supports approval,
clearance, or licensing of a medical product for marketing,” or suggest that additional information or labeling
of a new product is necessary.174 However, the most important fact about advisory panels is that their
168See Prothro, supra note 5 at note 86: (“Every drug must be approved as safe and eﬀective by the FDA before it can be
introduced into interstate commerce”); See 21 U.S.C. 355(a) (1994). The Federal Food Drug and Cosmetic Act of 1938 initially
imposed the drug “safety” requirement; this regulation was later updated to include drug eﬀectiveness prior to introduction
into interstate commerce. See 21 U.S.C. 355(b)(1)(a) (1994).
169Any company seeking new drug approval must submit applications to the FDA. An advisory review panel or committee
generally reviews the application after several phases of testing. The FDA reviews the ﬁndings and ﬁnal vote(s) of the advisory
panel and then issues a monograph in response to the new drug application; this monograph will classify a new drug in one of
three possible categories:
(1) Category I is applied if the new drug is “generally recognized as safe and eﬀective and not misbranded”; (2) Category
II is applied if the drug is not “generally recognized as safe and eﬀective or would result in misbranding”; or (3) Category
III is applied if the FDA determines that more testing data is required “on the basis of the Commissioner’s determination
that the available data are insuﬃcient to classify such conditions” under either Category I or Category II. See 21 C.F.R.
330.10(a)(6)(i)-(iii) (1995). See also Prothro, supra note 5 at note 86.
170Prothro, supra note 5 at note 86.
171See Id.
172See Carol Rados, “Advisory Committees: Critical to the FDA’s Product Review Process,” FDA Consumer (Jan.-Feb.
2004), available at http://fda.gov/fdac/features/2004/104 adv.html.
173Id.
174Id.
29ﬁndings are nonbinding; “while committee decisions and ﬁnal votes are very important to the FDA, the ﬁnal
regulatory decision rests with the agency.”175
In practice, the FDA has no problem disregarding the positive ﬁndings of an advisory panel. When caﬀeine
was proposed as an addition to antacids in hangover medications in 1991, an advisory panel was convened
regarding this proposal.176 Following the advisory panel’s decision that the inclusion of caﬀeine would be
safe and eﬀective, the FDA disregarded the panel’s ﬁndings.177 The agency concluded that
although moderate doses of caﬀeine did not generally cause gastrointestinal problems, the
population likely to ingest hangover medicine already suﬀered from gastrointestinal irritation
and might be harmed by caﬀeine’s stimulation of gastric secretions of hydrochloric acid.178
The agency therefore demonstrates that it adheres to a strict consumer safety policy regarding drug approval:
the FDA can classify potentially useful drugs as unsafe solely on the basis that consumer usage of those drugs
may ultimately be unsafe.179
The FDA has also demonstrated that failing any one of the three main approval criteria (safety, eﬀective-
ness, and proper labeling for stated purpose), is a suﬃcient rationale for the agency to withhold marketing
approval. One clear example of this strict enforcement involves cold and allergy medications:
175Id. See also “Human Drug Advisory Committees,” U.S. Food and Drug Administration Center for Drug Evaluation
and Research, available at http://www.fda.gov/cder/audiences/acspage/, for more information regarding the appointment and
function of advisory committees.
176See 56 Fed. Reg. 66,742 (1991).
177See 56 Fed. Reg. 66,746 (1991).
179See also “How Are Additives Approved for Use in Foods?” supra note 160, emphasizing the importance of FDA discretion
with regard to “expected levels of human consumption.” The FDA often decides to prohibit or limit use of a product based
on the idea that “the amount likely to be consumed” and “various safety factors” contribute to a belief that a potentially safe
product will tend to be used unsafely.
30For example, the FDA has prevented the use of caﬀeine in cold, cough, allergy, bronchodila-
tor and antiasthmatic drug products because it concluded that caﬀeine was either unsafe or
ineﬀective in combination with phenylpropanolamine and/or ephedrine or pseudoephedrine
or in combination with any cold, cough, allergy, bronchodilator, or antiasthmatic ingredient,
and either unsafe or ineﬀective (in combating lethargy) in cold preparations not containing
antihistamines.180
It is interesting to note that the FDA does approve the use of theophylline, the methylxanthine closely
related to caﬀeine, in bronchodilators because of its relaxing eﬀects on smooth muscle; however, the quantity
of caﬀeine required to make it an eﬀective bronchodilator is considered close enough to its toxic quantity for
the FDA to consider its use unsafe or ineﬀective.181
In reviewing caﬀeinated weight loss products like “Dexatrim,” the FDA, after advisory panel review, decided
that both caﬀeine and caﬀeine citrate had no valuable weight loss eﬀects for consumers; this prompted FDA
intervention in 1991.182 The agency both removed caﬀeinated weight loss products from the market and
threatened further regulatory action against manufacturers if they refused to remove caﬀeine from their
weight loss products within one year.183 Even though caﬀeine intake has in the past been attributed to
increased athletic function and metabolism, the FDA prefers to err on the side of caution and does not allow
the public to overmedicate unnecessarily.184
181See Goodman and Gilman, supra note 4 at 677. See also “What Are the Major Classes of Asthma Medications?” FAQ:
Asthma – General Information (Sep. 2000), available at http://www.radix.net/∼mwg/medclass.html, for a more detailed
description of the FDA’s speciﬁc approval of diﬀerent classes of asthma medications.
182See 21 C.F.R. 310.545(a)(20) (1995).
183See Id. See also 21 C.F.R. 310.545(d)(2) (1995).
184The FDA’s decision that caﬀeine does not correlate suﬃciently with weight loss is under new scientiﬁc investigation. See e.g.
M. H. Van Soeren and T.E. Graham, “Eﬀect of Caﬀeine On Metabolism, Exercise Endurance, and Catecholamine Responses
After Withdrawal,” available at http://www.elitetrack.com/caﬀeine5.pdf: (“We conclude the mechanism through which caﬀeine
acts as an ergogenic aid is unlikely to be through changes in available metabolic substrates or catecholamines but rather is
through some direct action of caﬀeine on tissues as yet to be described”). Whether caﬀeine stimulates increased metabolic
function or acts in some other way to boost body energy, potential weight loss links could be reevaluated in the future following
additional testing.
31Setting aside the numerous instances in which the FDA has intervened in the consumer drug market to
prevent unnecessary or unsafe caﬀeine use, a number of caﬀeinated drug products have been FDA-approved
and are readily used by consumers.
FDA has approved the use of caﬀeine in a number of over-the-counter (OTC) drug products.
For example, it has found caﬀeine to be safe and eﬀective as an ingredient in stimulant drug
products, used to ‘restore mental alertness or wakefulness during fatigue or drowsiness’....
In addition, the FDA has approved the use of caﬀeine in menstrual drug products, rec-
ognizing that it is a diuretic and a stimulant which can help women suﬀering from water
weight gain and fatigue during their menstrual or pre-menstrual periods. Finally, after years
of study and review, the FDA has recognized the eﬀectiveness of caﬀeine as an analgesic
adjuvant in aspirin and aspirin/acetaminophen products.185
Caﬀeinate is often “widely employed” in the treatment of many ordinary types of headache and fatigue, and
is even used in combination with an “ergot alkaloid in the treatment of migraine.”186
Once the FDA has approved the existence and production of a new caﬀeinated drug, it continues to monitor
consumer safety through strict labeling requirements.187 Contrary to caﬀeine food labeling requirements,
which only require the presence of caﬀeine on the ingredients list if it is an additive (i.e. sodas), caﬀeine in
drugs must be listed qualitatively on the label, and with signiﬁcant stimulant warnings.188 The regulation
speciﬁes that
186See Goodman & Gilman, supra note 4 at 678.
187See generally http://www.fda.gov, for basic drug labeling requirements. See also Prothro, supra note 5 at 79.
188See 21 C.F.R. 340.50 (1995). Subsection (a) speciﬁes that: (“the labeling of the product contains the established name of
the drug, if any, and identiﬁes the product as an ‘alertness aid’ or a ‘stimulant”’). Subsection (b) speciﬁes the requirements
for caﬀeinated product indications, but with the important restriction that: (“Other truthful and nonmisleading statements,
describing only the indications for use that have been established and listed...”); meaning that the FDA still pull the product
from the market even if the label is technically correct if they ﬁnd that consumers are being misled.
32The labeling of the product contains the following warnings under the heading ‘warnings’:
(1) The recommended does of this product contains about as much caﬀeine as a cup of
coﬀee. Limit the use of caﬀeine-containing medications, foods, or beverages while taking
this product because too much caﬀeine may cause nervousness, irritability, sleeplessness,
and, occasionally, rapid heart beat. (2) For occasional use only. Not intended for use as
a substitute for sleep. If fatigue or drowsiness persists or continues to recur, consult a
physician [or doctor]. (3) Do not give to children under 12 years of age.189
Furthermore, in 1999, the FDA approved a new monograph (generally eﬀective in April 2001) with more
detailed labeling requirements for over-the-counter drugs.190
Among the new over-the-counter labeling provisions are requirements that the labels “adhere to standard-
ized headings and subheadings, presented in a speciﬁed order,” as well as graphical restrictions including
“minimum requirements for type size, graphical highlights, leading (space between two lines of text), kerning
(spacing between letters),” and use of “connecting terms” previously required under the Code of Federal
Regulations.191 The updated regulation is intended to “further the safe and eﬀective use of these drug
products for consumers by making labels easier to read and understand.”192
The FDA’s continuing concerns regarding the labeling and warnings on caﬀeinated drugs are part of the
agency’s dedication to further minimizing consumer health risks. For example, one of the reasons the FDA
mandates standardized and legible drug content data is so that consumers can avoid using too much caf-
190See generally “New FDA Labeling Requirements for Over-the-Counter Drug Products,” Release #9B-118 (Sept. 1999),
available at http://www.actstesting.com/actsnews.nsf/0/860825D224E2E73285256802004637F3?open.
191See Id. Companies like ACTS Testing Labs (the sponsor of the site) are paid by companies to evaluate new drug labels for
potential FDA compliance problems.
192Id. Another separate issue of ever-increasing importance is the labeling of prescription drugs. In the December 22, 2000
Federal Register, a new FDA prescription drug labeling proposal was put forth, in response to (“increasing length and complexity
of labeling for new prescription drugs, and after many physicians said the current format can lead to confusion. The agency states
that the information most useful to doctors is contraindications, drug interactions, side eﬀects, and dosage and administration”).
See “FDA Caters to Physicians; A Proposed Rule for Redesigning Prescription Drug Labeling Can Help Save Physician Time
and Reduce Adverse Drug Events,” (Mar. 2001), available at http://devicelink.com/pmpn/archive/01/03/010.html. This
further underscores the importance the FDA places on accurate and safe labeling of drugs, and the diﬃculties in protecting
the consumer public; if expert physicians are having diﬃculty understanding and safely dispensing prescription medication, the
FDA is even more concerned about the ramiﬁcations of consumer self-medication with readily available over-the-counter drugs.
33feine in combination with other products, therefore both making consumers aware of likely side eﬀects and
reducing the potential for negative consequences from these side eﬀects.193
Perhaps the most important addition to the existing over-the-counter drug regulations is the codiﬁcation
of active ingredient listing requirements including the speciﬁc quantity of ingredients used. Prior to the
1999 ﬁnal rule on over-the-counter labeling requirements, the FDA did not require manufacturers to list the
quantities of active ingredients on their labels.194 Some sources posit that such regulation was, in the past,
unnecessary due to massive voluntary disclosure of active ingredient information; “under another voluntary
program begun in 1974, the member companies...have been including the quantities of active ingredients
on OTC drug labels.”195 The Nonprescription Drug Manufacturers Association, a trade organization that
encompasses the vast majority of all over-the-counter drug sales in the United States, was the impetus for
this general practice of voluntary disclosure.196
As part of the 1999 reforms, and partly due to the tremendous increase in the publicly available number
of herbal remedies, energy boosting supplements, and other new over-the-counter drug products, the FDA
issued regulations that codiﬁed the previous voluntary practice of active ingredient quantity labeling.197
Under the “Active Ingredients” section of the ﬁnal rule, the FDA notes that
193See Prothro, supra note 5 at 79-80. See also 53 Fed. Reg. at 6,100 and 6,103, discussing stimulant warning statements.
194See “Over-the-Counter Human Drugs: Labeling Requirements,” FDA Final Rule Re: 21 C.F.R. Parts 201, 330, 331, 341,
346, 355, 358, 369, and 701 (Mar. 1999), available at http://www.fda.gov/cder/otc/label/label-fr-reg.htm.
195See 60 Fed. Reg. 6,892, 6,897 (1995), cited in Prothro, supra note 5 at note 105. See also “Over-the-Counter Human
Drugs: Labeling Requirements,” supra note 194: (“At that time, the agency’s regulations encouraged (but did not require)
manufacturers to include the quantity per dosage unit in the labeling (330.1(j)). The vast majority of OTC drug products
already include such information in their labeling”).
196See Id.
197See “Over-the-Counter Human Drugs: Labeling Requirements,” supra note 194: (“As a result of the statutory change,
this ﬁnal rule makes clear that the established name and quantity of each active ingredient must be included in the required
information set forth in 201.66(c), in the location and format established by the agency”).
34Section 201.66(c)(2) requires the heading “Active Ingredient(s),” followed by the established
name and the quantity of each active ingredient per dosage unit. For products marketed
without a discrete dosage unit, such as topical OTC drug products, the proportion of each
active ingredient must be stated instead of the quantity, unless otherwise speciﬁed in an
applicable monograph or approved drug application. This provision incorporates a recent
amendment to section 502(e) of the act under FDAMA...to require that the quantity...of
each active ingredient appear in the labeling of all OTC drug products intended for human
use.198
This means that consumers can now be certain to know exactly how much caﬀeine they consume when using
over-the-counter drugs. While there is still “a signiﬁcant discrepancy in caﬀeine content across OTC drugs,”
consumers are “made aware of it and are warned against excessive consumption.”199
Another way the FDA maintains control over caﬀeinated drugs after market approval is through dosage
limits; for example, while certain analgesics use caﬀeine both as an adjuvant and a stimulant, the FDA
planned to limit the amount of caﬀeine to “64 or 65 mg per dose irrespective of the amount of analgesic
in the dose.”200 The low dosage was the “demonstrated minimum eﬀective caﬀeine dose, and was chosen
based on agency concerns about the potential of caﬀeine to foster analgesic misuse.”201 Because the FDA
perceives caﬀeine habituation as a problem, albeit a reasonably minor one, drugs that incorporate caﬀeine
must still do so at doses that are clinically eﬀective while not unnecessarily or deliberately causing addictive
psychotropic responses.202
Even in drug products in which the FDA generally allows caﬀeine to be used in small amounts, such as
199See Prothro, supra note 5 at 80.
200See F.D.C. Rep., 3 The Tan Sheet 19 (1995), cited in Prothro, supra note 5 at note 99.
201See Id., cited in Prothro, supra note 5 at 79.
202See Id.: (“Habituation to caﬀeine is well documented in the scientiﬁc literature...caﬀeine in analgesic combinations at
concentrations as low as 64 mg can exert some psychotropic eﬀect”).
35aspirin or acetaminophen pain relievers, approval does not extend unequivocally to any similar class of drug
seeking to include caﬀeine. Further, even if permission is granted to produce and market a new drug, there is
still strict FDA supervision of marketing claims made on behalf of caﬀeine-containing drugs.203 For example,
in 1997, Bristol-Myers Squibb attempted market a new caﬀeine-containing drug similar to a commonly used
pain reliever called “Norﬂex,” which contains the active ingredient orphenadrine citrate.204
Norﬂex (orphenadrine citrate) is used “to relieve the pain and discomfort associated with musculoskeletal
injuries and conditions.”205 In its attempt to market its new tablet combining orphenadrine citrate, aspirin,
and caﬀeine, Bristol-Myers Squibb and its subsidiaries released promotional materials claiming this new
tablet was “AB Rated, Therefore Bioequivalent to Norﬂex.”206 However, the FDA demanded immediate
removal of all promotional material, stating that “Norﬂex contains only a single active agent, namely, or-
phenadrine citrate.... thus these products are not AB rated and are not bioequivalent.”207 The FDA was
primarily concerned about the potential for interaction eﬀects that could result from the use of the additional
active ingredients caﬀeine and aspirin combined with orphenadrine citrate.208 Thus, even after approval, the
FDA maintains a vigilant watch over the caﬀeine-containing consumer drug pool in order to minimize the
potential for negative health consequences among consumers.
203See generally Moore, supra note 129.
204See Stephen Sherman, “Warning Letter to Thomas E. Costa, Vice President and Counsel, U.S. Pharmaceutical Group,
Bristol-Myers Squibb Company Re: ANDA 74-817 Orphenadrine Citrate, Aspirin and Caﬀeine Tablets,” FDA Division of Drug
Marketing, Advertising and Communications (July 1997), available at http://www.fda.gov/cder/warn/july97/orphen.pdf.
205See “Orphenadrine Citrate Drug Information,” Pharmacy Health (2003), available at
http://www.pharmacyhealth.net/d/orphenadrine-citrate-6471.htm.
206See Sherman, supra note 204.
207Id.
208See Id.: (“There is signiﬁcant risk and potential danger to consumers if Apothecon’s product were used inadvertently in
place of Norﬂex by a consumer who is allergic to aspirin or who has peptic ulcers or coagulation abnormalities.... BMS should
immediately, clearly, and prominently alert health care professionals of this serious error, that its orphenadrine citrate, aspirin
and caﬀeine tablets are not bioequivalent to Norﬂex, and the potential risks of using this product....”).
36IV. The Future of Caﬀeine Regulation: Reexamining the FDA Approach
Recognizing the American public’s curious infatuation with caﬀeine, the FDA, through its regulation of both
foods and drugs, has been trying to keep the public informed about caﬀeine and protected from any adverse
eﬀects. In the 1980s, after data suggested a correlation between caﬀeine and birth defects, the FDA was
hard at work, issuing press releases, consumer warnings, and labeling requirements as part of its educational
campaign.209 As with any food or drug, as the FDA perceives consumer health concerns, it intervenes to
correct problems through issuance of regulations and through direct contact with manufacturers.210 If no
way can be found to release and market a particular product such that it will be safe and eﬀective for
consumer use, the FDA issues an order to pull the product from the market entirely.211
A. More FDA Regulation: No Additional Need, No Productive Purpose
To date, the FDA has not seen ﬁt to issue a general ban on the inclusion of caﬀeine in foods and drugs because
such a ban is unwarranted. Since caﬀeine has been used safely for so long in so many foods and beverages, a
simple risk-beneﬁt calculus would lead to the general conclusion that “consumers be permitted to make their
own judgments about risks on the basis of complete and accurate information about the hazards involved.”212
With the dearth of long-term caﬀeine study data raising alarm, and the prevalence of caﬀeine in the consumer
products market, the FDA should remain on guard for future indications of dangerous health correlations.
209See Prothro, supra note 5 at 82-83 for further summary.
210See generally “About the U.S. Food and Drug Administration,” available at http://www.fda.gov/opacom/hpview.html.
211See Id.
212Peter B. Hutt, “The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food,” 33 Food
Drug Cosm. L. J. 505, 537 (1978).
37However, following the recent passage of uniform over-the-counter drug labeling requirements,213 there is no
further market intervention that would be necessary or desirable on the part of the FDA.
Some sources have suggested that there is a problem with caﬀeine regulation as applied to foods, asserting
that caﬀeine content labeling on foods is the next logical step in FDA consumer protection.214 The basic
argument for this position is that consumers cannot make informed choices about their daily caﬀeine intake
if the speciﬁc amount of caﬀeine is only listed on certain drug products.215 The argument also notes that
“caﬀeine quantities vary signiﬁcantly in foods,” and generalizes that consumers may be misled if, for example,
a single serving of chocolate can contain anywhere from six to twenty-ﬁve milligrams of caﬀeine.216
Any argument that favors the extension of caﬀeine quantity labeling to foods is fundamentally ﬂawed. While
it might be beneﬁcial to know the exact amount of caﬀeine in any given food, this is not always possible. A
new coﬀee study suggests (among other things) that “java’s caﬀeine jolt varies naturally,” and that “there
are many variables that contribute to caﬀeine content from cup to cup, such as the type of bean, roasting and
brewing methods, and grind.”217 This variance is further exacerbated by recent ﬁndings that “the caﬀeine
content of specialty coﬀee beverages varies widely from day to day as well as from coﬀee shop to coﬀee
shop.”218
While the study data suggests that American caﬀeine consumption may be on the rise, researchers contend
213See “Over-the-Counter Human Drugs: Labeling Requirements,” supra note 194.
214See Prothro, supra note 5 at 83.
215See Id.
216See Id.
217See Jennifer Warner, “Specialty Coﬀee’s Caﬀeine Jolt Varies,” WebMD Health Archives (Oct. 23, 2003), available at
http://my.webmd.com/content/article/75/89869.htm, ref. R. McCusker, 27 J. Analytical Toxicology 520, 520-522 (Oct.
2003).
218Id. The study refers to a comparison between “Starbucks” coﬀee and “Dunkin Donuts” coﬀee, and ﬁnds that the average
medium sized coﬀees from Starbucks contained 259 milligrams of caﬀeine, as compared to 143 milligrams of caﬀeine for Dunkin
Donuts coﬀee. Further, the study noted that at identical storefront locations, the caﬀeine content of a Starbucks medium coﬀee
could range anywhere from 259 to 564 milligrams.
38that “coﬀee drinkers might have to live with uncertainty when it comes to how much caﬀeine” they take
in from their daily coﬀee.219 This same logic applies to all other natural sources of caﬀeine in foods; if the
caﬀeine content in a serving of chocolate can vary anywhere from six to twenty-ﬁve milligrams, it would
be an unjustiﬁable burden on manufacturers to have them give a best guess at the caﬀeine content on an
individual item. Further, the quantity of caﬀeine added to products like soda, while not listed explicitly on
the label, is easily enough obtained since content data is published by soft drink manufacturers.220
Fortunately, the FDA has long held to a policy of rarely including consumer health warnings on foods,
and doing so only in such instances deemed absolutely necessary.221 The fact that caﬀeine has been safely
consumed for so long, coupled with the agency’s fear of consumer analysis paralysis, suggests that further
regulatory intervention is both impractical and undesirable.222
B. New Scientiﬁc Information Means Diminished Concern
The advancement of new scientiﬁc data regarding the positive and neutral health impacts of caﬀeine prompted
the FDA’s public aﬀairs staﬀ to summarize some of the administration’s previous concerns about caﬀeine.223
219See Id.
220See e.g. “Caﬀeine in Beverages,” available at http://www.nsda.org/WhatsIn/caﬀeinecontent.html. The National Soft
Drink Association voluntarily makes caﬀeine content data public.
221See 58 Fed. Reg. 2850, 2872 (1993).
222See e.g. Lars Noah, “The Imperative to Warn: Disentangling the ‘Right to Know’ from the ‘Need to Know’ About Consumer
Product Hazards,” 11 Yale J. on Reg. 293, 315-20 (1994). See also Prothro, supra note 5 at 86, admitting: (“[a] caﬀeine
warning label would not be useful. There are simply too many labels ‘warning’ consumers. Their combined eﬀect is overload.
Consumers react either by ignoring all warnings, including ones of deadly danger, or by paying too much attention to the
warnings and avoiding all products bearing such statements, including useful and beneﬁcial products”).
223See Chris Lecos, “Caﬀeine Jitters: Some Safety Questions Remain,” FDA Public Aﬀairs Staﬀ, available at
http://www.hoptechno.com/book4.htm.
39In 1980, FDA was confronted with various studies that aroused concern about the possible
association of caﬀeine in the human diet with numerous health problems. Of immediate
concern was the study that demonstrated caﬀeine’s potential for causing birth defects in
animals. Was there a danger to humans? The agency said that it didn’t know. So, it
chose to lean on the side of caution by warning pregnant women and, at the same time,
asking industry and the scientiﬁc community to do more studies on caﬀeine’s health eﬀects.
These have now been done, and they generally have produced less worrisome results. For
that reason, and because FDA determined that some of the earlier studies were faulty,
inconclusive, or contradicted by later ﬁndings, the concern about caﬀeine has lessened.224
A change in the regulatory posture of caﬀeine is unsurprising, as the FDA continues to monitor and update
the level of regulation on consumer products based on the continued development of laboratory data.225
What is surprising, however, is the continued outpouring of new data suggesting potential positive health
eﬀects of caﬀeine use. For example, the National Parkinson Foundation has researched the posited inverse
relationship between caﬀeine intake and Parkinson disease for years, but with “equivocal” results at best.226
However, a thirty-year follow-up case review published in the Journal of the American Medical
Association indicates that “higher coﬀee and caﬀeine intake is associated with a signiﬁcantly lower incidence
of Parkinson disease.”227 While it is certainly not the last word on this newly-established caﬀeine correlation,
it serves as proof-positive that time and medical data can and have signiﬁcantly diminished the necessary level
225See generally http://www.fda.gov, for information regarding continuing post-approval regulation of food additives and
drugs.
226See Abraham Lieberman, “Coﬀee and Parkinson Disease: Is Starbucks the Treatment?” National Parkinson Foundation
(2000), available at http://www.parkinson.org/coﬀee.htm.
227Id.; describing a May 2000 study released in the JAMA that involved 8,004 Japanese-American men over a period of 30
years. The study utilized (“Incident Parkinson disease (number of participants who developed Parkinson during the study) by
amount of coﬀee intake (measured at study enrollment and 6-year follow-up) and by total dietary caﬀeine intake (measured
at enrollment)...”) as its main outcome measure, and further found that: (“Age-adjusted incidence of Parkinson disease
declined consistently with increased amounts of coﬀee intake, from 10.4/10,000 person-years in men who drank no coﬀee to
1.9/10,000 person-years in men who drank at least 280z/d. Similar relationships were observed with total caﬀeine intake and
caﬀeine from non-coﬀee sources.... Other nutrients in coﬀee, including niacin, were unrelated to Parkinson disease incidence.
The relationship between caﬀeine and PD was unaltered by intake of milk and sugar”). See also Tomas DePaulis, PhD
research scientist for Vanderbilt University’s Institute for Coﬀee Studies, quoted in Sid Kirchheimer, “Coﬀee: The New Health
Food? Plenty of Health Beneﬁts Are Brewing in America’s Beloved Beverage,” WebMD Feature (Jan. 26 2004), available
at http://content.health.msn.com/content/article/80/96454.htm?printing=true: (“In fact, Parkinson’s drugs are now being
developed that contain a derivative of caﬀeine based on this evidence”).
40of public health concern with regard to caﬀeine use. Another example of conﬂicting
caﬀeine data that has been reconsidered recently involves correlations between caﬀeine intake and health
risks for women who are either seeking to become pregnant, or who are already pregnant or nursing. A small
1988 study suggested that low to moderate caﬀeine consumption might decrease female fertility; however, the
scientists involved “acknowledged that delayed conception could be due to other factors they did not consider,
such as exercise, stress, or other dietary habits.”228 Further study data has since prompted the International
Food Information Council (IFIC) to dismiss the presumed link between caﬀeine and infertility.229 The IFIC
and the Organization of Teratology Information Services (OTIS) further investigated correlations between
caﬀeine intake and risks of birth defects, low birth weight, and caﬀeine transfer to infants through breast
milk; the results demonstrate that, though high levels of caﬀeine intake are potentially dangerous to infants
during gestation and breast feeding, low to moderate levels of caﬀeine intake are less problematic than
previously thought.230 The wave of recent positive caﬀeine study data has even caused some health
professionals and consumers to wonder if coﬀee is “the new health food.”231 Besides posited correlations
between caﬀeine intake and reduced risk of Parkinson disease, a recent Harvard study also suggests that
persistent caﬀeine use might also reduce the risk of type-2 diabetes.232
228See “Caﬀeine, CERHR Study,” supra note 89.
229See Id.: (“Since then, larger, well-designed studies have failed to support these ﬁndings. In 1990, researchers at the Centers
for Disease Control and Prevention and Harvard University examined the association between the length of time to conceive and
consumption of caﬀeinated beverages.... The researchers found that caﬀeine consumption had little or no eﬀect on the reported
time to conceive in those women who had given birth. Caﬀeine consumption also was not a risk factor for infertility. [In] 2001,
OTIS reviewed the studies examining caﬀeine eﬀects on fertility and concluded that ‘low to moderate caﬀeine consumption
(<300mg/day) does not seem to reduce a woman’s chance of becoming pregnant”).
230See Id.: (“Groups such as OTIS, March of Dimes, and Motherisk reviewed studies examining caﬀeine intake during
pregnancy and are in agreement that high caﬀeine intake (>300mg/day, equivalent to more than 3 cups of coﬀee/day)
should be avoided during pregnancy. There is also general agreement that low caﬀeine intake (<150mg/day, about 1-1/2
cups of coﬀee) during pregnancy is not likely to harm the unborn child. See also “Caﬀeine and Women’s Health,” supra
note 4. See also “Caﬀeine in Pregnancy,” March of Dimes Quick Reference and Fact Sheets (April 2004), available at
http://www.marchofdimes.com/professionals/681 1148.asp. See generally “Caﬀeine and Pregnancy,” Organization of Tera-
tology Information Services (Dec. 2001), available at http://www.otispregnancy.org/pdf/caﬀeine.pdf.
231See Kirchheimer, supra note 227.
232See Id., ref. Harvard School of Public Health study by Frank Hu, 140 Annals of Internal Med. 1, 1-8 (Jan 2004).
41After analyzing data on 126,000 people for as long as 18 years, Harvard researchers calculate
that compared with not partaking in America’s favorite morning drink, downing one to three
cups of caﬀeinated coﬀee daily can reduce diabetes risk by single digits. But having six cups
or more each day slashed men’s risk by 54% and women’s by 30% over java avoiders.233
While these (and other similar) ﬁndings would beneﬁt from more research, the overarching trend in caﬀeine
data over the last ﬁve to ten years is positive; “overall...coﬀee is far more healthful than it is harmful...the
evidence is very strong that regular coﬀee consumption reduces risk of Parkinson’s disease and for that, it’s
directly related to caﬀeine.”234 The proliferation of scientiﬁc information
available through the internet has a large upside for consumers: useful ﬁndings of new medical studies (in-
cluding the ones discussed herein) can reach the consumer public faster than ever before. Internet services
such as “MSN Health” and “WebMD” even have newsletter services, such that health product consumers
can make more informed product purchasing decisions as a result of newly available information.235 For
caﬀeine users, this translates to increased awareness of product eﬀects, such that people can better regulate
their diets to suit their individual health needs.236
C. Residual Skepticism and Incomplete Scientiﬁc Information The availability of new caf-
feine health data does not mean that the FDA should rest on its regulatory laurels. The Parkinson disease,
pregnancy, and diabetes studies together illustrate that with the increase in the number of scientiﬁc ex-
periments conducted and the dramatic expansions of available scientiﬁc data and information, the FDA
and the American public (as consumers of health information) must be cautious not to jump too quickly
to health-related conclusions. The Parkinson study admits that “the study design is such as to prevent
the researchers from concluding, deﬁnitively, that coﬀee or caﬀeine directly protect against development of
234See Id., quoting Tomas DePaulis, PhD research scientist for Vanderbilt University’s Institute for Coﬀee Studies.
235See e.g. http://www.webmd.com, and http://www.health.msn.com; website visitors can subscribe to particular categories
of health-related newsletters, such that they will be emailed new updates on their topics of choice.
236See Id. Thousands of visitors frequent WebMD daily; an in-site search for “caﬀeine” yielded 722 documents discussing
diﬀerent aspects of caﬀeine, including latest medical ﬁndings. Arguably, this means that new information is readily available
to consumers.
42Parkinson disease.”237 It instead recognizes that “the possibility that caﬀeine may have a protective eﬀect
against developing Parkinson disease must be investigated further.”238 The FDA admits
that the risks associated with caﬀeine use have been at least overstated in the past;239 even so, sources at
the FDA continue to encourage consumer wariness, fearing unknown future potential eﬀects from long-term
exposure.
However, FDA is also saying that while there is a basis for being less concerned about
caﬀeine’s impact on health, some questions remain unanswered. The agency continues to
stress that caﬀeine is a chemical stimulant that aﬀects the central nervous system. It is a
widely used food additive to which some people are more sensitive than others. It could have
other, still unknown, eﬀects. But determining what these eﬀects are is not a simple matter,
as some studies have indicated, since other factors - such as smoking, alcohol consumption,
poor diet, and drug use - also can aﬀect human health. From a regulatory standpoint,
FDA will continue to monitor caﬀeine use in foods and how much of it people consume.
Meanwhile, consumers probably should adhere to some age-old advice: moderation makes
good sense.240
Many consumers also decry the lack of caﬀeine content data on food products such as sodas, fearing the
addictive properties of the drug are more dangerous than the FDA recognizes.241
Besides the obvious potential problems with new scientiﬁc data, including consumer over-reliance and incom-
plete or uncertain conclusions, caﬀeine and other drug data can be taken out of context or manipulated in
such a way as to cause an artiﬁcial sense of consumer security or unnecessary fear of drug products. For ex-
237See Lieberman, supra note 226. The study also humorously notes that: (“At this time there is not enough evidence to urge
you to go to Starbucks and drink 6 caf´ e-lattes a day”).
238Id.
239See “Caﬀeine Jitters,” supra note 223.
241See e.g. Patricia Lieberman, “Label Caﬀeine as a Drug – Even in Soda,” New York Times Letter to the Editor, Aug.
26, 1997, available at http://www.junkscience.com/news/soda.html: (“[t]he article ignored one of the worst aspects of adding
caﬀeine to soda. Introducing a mildly addictive drug to soft drinks encourages children to drink sugar water instead of more
nutritious beverages like fruit juice and low-fat milk....The Food and Drug Administration should require that soft drinks and
other foods be labeled with their caﬀeine content to help parents decide what their children should drink”).
43ample, a recent alarmist email message was sent to thousands of consumers regarding phenylpropanolamine,
a common product in cough and cold medicines, weight control drugs, and decongestants.242 Among other
claims, the email letter suggested that “all drugs containing phenylpropanolamine are being recalled,” and
that consumers should “stop taking anything containing this ingredient” because it “has been linked to in-
creased hemorrhagic stroke...among women ages 18-49 in the three days after starting use of medication.”243
While it is true that the FDA is seriously concerned over the inclusion of phenylpropanolamine in common
over-the-counter products, particularly after a Yale research study linked it to increased risk of hemorrhagic
stroke,244 the FDA already took the necessary regulatory measures in the year 2000.245 Further, the email
letter grossly overstates the linkage between phenylpropanolamine and immediate health risk.246
The “drug hoax” as described is not included to suggest that FDA and other consumer health warnings should
be taken lightly; rather, it serves to illustrate the downside of the information age. With the explosion of
internet technology, consumers live in an age in which scientiﬁc information is more readily available than
ever before, and this has consumer awareness beneﬁts.247 With this new ease of access to data comes
a corresponding responsibility to carefully consider the sources and validity of available information, the
overarching concern being that the quality of health related statements relied upon by consumers is oftentimes
dubious. Provided that consumers stick to reputable sources of information, however, increased connectivity
242See “Drug Recall Hoax,” Trend Micro Security Info (2004), available at http://www.trendmicro.com/vinfo/hoaxes/hoax5.asp?HName=Drug+Recall+Hoax.
243Id.
244See Ralph Horwitz et al., “Phenylpropanolamine & Risk of Hemorrhagic Stroke: Final Report of The Hemorrhagic Stroke
Project,” (May 10, 2000), available at http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3647b1 tab19.doc.
245See “Phenylpropanolamine (PPA) Information Page,” CDER (2000), available at
http://www.fda.gov/cder/drug/infopage/ppa/default.htm: (“The Food and Drug Administration (FDA) is taking steps
to remove phenylpropanolamine (PPA) from all drug products and has requested that all drug companies discontinue
marketing products containing PPA. In addition, FDA has issued a public health advisory...”).
246While the letter described the health risks as “URGENT,” the FDA concluded that: (“Although the risk of hemorrhagic
stroke is very low, FDA recommends that consumers not use any products that contain PPA”). See “Phenylpropanolamine
(PPA) Information Page,” supra note 245. See also “Drug Recall Hoax,” supra note 242.
247See generally “New Scientiﬁc Information Means Diminished Concern” section above.
44can lead to better health decision-making.248
D. A Hypothetical Scenario Considered: Caﬀeine as a New Food Additive or Drug
Though the policy of consumer moderation is still an entirely sensible approach, this Paper generally contends
that, in the face of newer and better data, caﬀeine is much safer than older studies and reviews have
suggested. This ﬁnding, however, prompts an interesting hypothetical consideration: since caﬀeine is and
has been so pervasive in the marketplace (naturally, as a food additive, and in drugs), it has not been
forced to undergo the more complex and time consuming contemporary processes of food additive or drug
approval. It is worthwhile, then, to hold caﬀeine up to current regulatory process and scrutiny, in order to
better demonstrate that previous health concerns regarding caﬀeine were inﬂated.
1. Caﬀeine as a Newly-Proposed Food Additive
A company must ﬁrst petition the FDA for approval before marketing a new food additive.249 A food
additive petition “must provide convincing evidence that the proposed additive performs as it is intended.”250
Usually, part of the relevant data comes from animal studies “using large doses of the additive for long
periods” to satisfactorily demonstrate that the substance “would not cause harmful eﬀects at expected levels
248See e.g. http://www.webmd.com, which is a highly traﬃcked and well respected contemporary source of consumer health
information.
249See “How Are Additives Approved for Use in Foods?” supra note 160.
250Id.
45of human consumption.”251 The FDA considers many factors, including “the composition and properties of
the substance, the amount likely to be consumed, its probable long-term eﬀects and various safety factors”
when weighing its approval decisions.252 Since one-hundred percent safety is not practical for any substance,
the FDA must instead determine if the proposed new additive is safe enough “under the proposed conditions
of use,” and “based on the best scientiﬁc knowledge available.”253
Now, assume the existence of a new soda company, “Hypo-Cola,” in a consumer world that is entirely familiar
with the GRAS list and with the proper process for soda manufacturing, but that is caﬀeine na¨ ıve. First,
the Hypo-Cola company petitions the FDA to have its new additive, the methylxanthine chemical caﬀeine,
approved for consumer use.254 As a potential new food additive, the FDA wants to know caﬀeine’s intended
purpose, as well as the company’s rationale for including it in its new soft drink.
This is the ﬁrst potential snag in the regulatory process; without GRAS list status, and without a world
in which caﬀeine use is assumed to be both natural and commonplace, Hypo-Cola likely has some diﬃculty
explaining the need for caﬀeine’s inclusion in sodas. While the National Soft Drink Association claims both
that “caﬀeine has a classic bitter taste that enhances other ﬂavors,” and that “small amounts of caﬀeine
are added to soft drinks as part of the ﬂavor proﬁle,”255 Hypo-Cola has to convince the FDA of the validity
of those claims while minimizing the signiﬁcance of the chemical’s stimulant properties, or else risk more
cumbersome drug regulation.
Getting caﬀeine approved as a ﬂavor additive may be slightly more diﬃcult in light of a recent Johns Hopkins
251Id. The FDA also notes that: (“approximately 100 new food and color additives petitions are submitted to the FDA
annually”), though most are for (“indirect additives such as packaging materials”). Further, any available human study data
may be submitted to the FDA along with animal test data.
252Id. See generally “Food Safety: A Team Approach,” supra note 128.
253Id.
254For purposes of this hypothetical exercise, assume that all the current laboratory data on caﬀeine is known to the scientiﬁc
and regulatory communities.
255See “What’s In Soft Drinks?” National Soft Drink Association (Oct. 2003), available at
http://www.nsda.org/softdrinks/History/whatsin.html.
46University study, which found that “only two out of 25 hard-core cola drinkers were able in a blind taste
test to detect whether a soda sample contained caﬀeine.”256 While the size and format of the study are
disputed by the National Soft Drink Association,257 the results might cause the FDA to take a closer look
at caﬀeine’s inclusion in new soft drinks, and the potential for mandatory labeling requirements. However,
since “vendor intent” is a strong indicator of whether a substance will be considered a food or a drug,258
and since there is not suﬃcient evidence to suggest ulterior motivation on the part of soda manufacturers,
Hypo-Cola can likely proceed with the FDA approval process.259
The FDA then considers the chemical properties of the new additive, potential consumer use of the product
(including the amount likely to be consumed), and the likelihood of long-term consumer health risks. Hypo-
Cola has to provide evidence suﬃcient to satisfy the FDA’s consumer safety concerns.260 Assuming the
company has mustered all relevant study data, including suﬃcient animal laboratory data to show that the
stimulant eﬀects of caﬀeine are generally harmless, and further assuming that Hypo-Cola will be using a
small enough amount of caﬀeine so as not to injure public health,261 the FDA might approve the use of
caﬀeine as a new soft drink ﬂavoring additive.
If a new additive is approved, the FDA “issues regulations that may include the types of foods in which
it can be used, the maximum amounts to be used, and how it should be identiﬁed on food labels.”262 As
256See Neil Osterweil, “Study: Caﬀeine May Add Zing to Cola, But It Doesn’t Add Flavor,” WebMD Medical News Archive
(Aug. 14, 2000), available at http://my.webmd.com/article/27/1728 60353.htm.
257See Id.: (“Too few people were tested, too little science was used in the testing and too much opinion is contained in the
conclusions”).
258See generally Mathews, supra note 142.
259A separate, highly contentious query involves the notion that caﬀeine is only included in sodas to make them more addictive.
In examining the websites of every major soda company, in addition to the website of the National Soft Drink Association, the
companies make it uniformly clear that they use caﬀeine as part of a soda’s “ﬂavor proﬁle.” Therefore, taste experiments like
the aforementioned Johns Hopkins study, however methodologically problematic, may attract FDA focus.
260In other words, the company must demonstrate that the product is “safe and wholesome.” See generally “The Food and
Drug Administration: An Overview,” supra note 131.
261See e.g. 52 Fed. Reg. 18,923, 18,925 (1987).
262See “How Are Additives Approved for Use in Foods?” supra note 160.
47applied to Hypo-Cola, this means that the company places caﬀeine on the list of ingredients, though not
necessarily the speciﬁc amount used.263 Once the product is released and marketed for consumer use, FDA
oﬃcials continue to monitor the level of American consumption of the new additive and the results of any
new product safety research; this is to assure that the use of the product continues to be within safe limits.264
The FDA will take no aﬃrmative steps to ban or further limit caﬀeine as a food additive so long as the
long-term study data continue to show no major harmful eﬀects of its intake.265
2. Caﬀeine as a Newly-Proposed Drug
While the food additive approval process may be somewhat more complicated today than it was in the past,
“drug development in the United States has undergone many changes in the past 25 years,” and few people
“fully realize the complexities involved in developing a new drug.”266 In fact, the drug development process
occurs in several stages:
263Under the current regulatory regime, soft drink companies are not required to list the speciﬁc quantities of caﬀeine used
on the products themselves; however, many companies and sources, including the International Food Information Council
Foundation and the National Soft Drink Association, publish caﬀeine content data for interested consumers voluntarily. See
e.g. “Caﬀeine Content of Soft Drinks,” supra note 161.
264See “How Are Additives Approved for Use in Foods?” supra note 160.
265See Id. The FDA also has several methods of supervising products already in the marketplace, including ARMS: (“In
addition, FDA operates an Adverse Reaction Monitoring System (ARMS) to help serve as an ongoing safety check of all
additives. The system monitors and investigates all complaints by individuals or their physicians that are believed to be
related to speciﬁc foods; food and color additives; or vitamin and mineral supplements. The ARMS computerized database
helps oﬃcials decide whether reported adverse reactions represent a real public health hazard associated with food, so that
appropriate action can be taken”).
266See Moore, supra note 129 at 1244.
48Once a promising compound is identiﬁed, it must undergo preclinical testing, have an Inves-
tigational New Drug Application ﬁled with the U.S. Food and Drug Administration (FDA),
and proceed through clinical testing. When suﬃcient information is gained, a marketing
application is ﬁled with the FDA, who identiﬁes it as a New Drug Application for drugs or a
Biologics License Application for biologics. After FDA review and approval, postmarketing
studies are frequently performed. The FDA and Congress have undertaken several initiatives
to expand access and to accelerate drug development and review of investigational drugs
for life-threatening and/or serious illnesses. Although the ultimate goal is to bring safer
and more eﬀective medical products to patients in a timely manner, multiple challenges face
those who participate in drug development.267
Of every ﬁve-thousand to ten-thousand new drug compounds that will be subjected to the FDA approval
process, only an average of one “will proceed through development to Food and Drug Administration ap-
proval.”268
Further, recent estimates suggest that “developing a new drug requires approximately 10 to 15 years”; this
process costs an estimated 897 million dollars.269 Though the temporal and monetary costs associated
with new drug development are high, the FDA has recurring interests in accurate “statistical methods for
handling subgroups in the design and analysis of clinical trials,” as well as in “methods to assure data
integrity,” such that the agency can be sure that new compounds released to market are safe and eﬀective
for human consumption.270
Though the FDA admits it has limited knowledge regarding the drug development process, and has many
diﬀerent pressures to weigh when considering the safety of a newly created drug, it is still responsible for
creating the standards by which consumer health is protected; this means a more costly and time-consuming
268See Id.
269Id.
270See Charles Anello, “Emerging and Recurrent Issues in Drug Development,” 18 Statist. Med. 2301, 2301-2309 (1999).
49process for drug manufacturers.271
In setting standards, FDA functions amid a number of tensions. There is the desire of many
people, including much of the academic community, to have more information about a drug
before it has been approved. There are special interest groups...who want to be represented
in studies to attain information speciﬁc to them. Consumer protection advocates want to
have drugs worked-up well and thoroughly evaluated for safety and eﬃcacy before getting
on the market. On the other hand, there are economic pressures to get drugs on the market
as soon as possible, and these are highly valid.272
With that as the general regulatory backdrop, now assume the existence of a new drug manufacturer, “Hypo-
Stim.”
Hypo-Stim has discovered a new methylxanthine compound called caﬀeine. The company suspects that the
drug will be a good mild stimulant, though it may have other potential uses. Hypo-Stim therefore wants
to test the product, in hopes that it can eventually garner FDA approval for marketing.273 The process
begins with preclinical research; “after a promising compound is identiﬁed, much work occurs before human
exposure, usually in vitro and with animal testing.”274
The general goal of preclinical research and testing is to weed out potentially dangerous compounds as
much as possible prior to human clinical trials, therefore minimizing risk exposure for human test subjects
later on.275 Also, preclinical trials give the drug sponsor or manufacturer the initial opportunity to test
whether the new substance will be commercially viable, prior to the FDA having to interrupt production or
271See Janet Woodcock, “An FDA Perspective on the Drug Development Process,” 52 Food and Drug L. J. 145, 145-150
(1997).
273Due to the complexity of the drug approval process, the hypothetical will not explore every aspect of drug approval –
space and time prohibit an exhaustive treatment of this subject. The hypothetical is intended only to demonstrate some of
the potential concerns the FDA would raise with caﬀeine if it were a new drug compound seeking approval under the current
regulatory regime.
274See Moore, supra note 129 at 1247.
275Id. See also Shalala and Woodcock et al., supra note 267.
50marketing.276 Preclinical trials involve the use of numerous kinds of studies:
Usual types of studies that are performed include safety pharmacology studies (to assess
drug eﬀect on vital organ systems, such as the cardiovascular system, the respiratory system,
and the central nervous system), single-dose acute toxicity studies, repeated-dose toxicity
studies, local tolerance studies, at least part of the genotoxicity studies (bacterial reverse
mutation test and chromosomal damage test), and possibly carcinogenicity studies.277
Since caﬀeine usage has been linked to alterations in central nervous system, cardiovascular system, and
(though less so) to respiratory system functioning,278 Hypo-Stim will likely have to engage in a large battery
of expensive preclinical trials, in order to satisfactorily demonstrate that the quantitative eﬀect on those
body systems is insuﬃcient to trigger health concerns in humans. Further, caﬀeine’s LD50 will be recorded
in laboratory research; this data will inﬂuence whether the company considers going forward with clinical
testing.279
Though caﬀeine does stimulate several of the body’s major organ systems, study data in the last twenty-ﬁve
years has shown that these eﬀects are generally mild provided that toxic quantities are not ingested.280
Therefore, Hypo-Stim can likely proceed out of the preclinical phase and into clinical trials. However, “once
the decision is made from preclinical testing that use of the medical product appears promising and clinical
testing should proceed,” an IND, or Investigational New Drug application, must be ﬁled by the drug’s
sponsor with the FDA “before research studies begin with a new compound in human subjects.”281 The
drug sponsor, in this case Hypo-Stim, is the “person who takes responsibility for and initiates a clinical
276See Woodcock, supra note 271.
278See generally Goodman & Gilman, supra note 4.
279See also “Investigational New Drug (IND) Application Process,” available at http://www.fda.gov/cder/regulatory/applications/ind page 1.htm:
(“During a drug’s early preclinical development, the sponsor’s primary goal is to determine if the product is reasonably
safe for initial use in humans, and if the compound exhibits pharmacological activity that justiﬁes commercial development.
When a product is identiﬁed as a viable candidate for further development, the sponsor then focuses on collecting the data
and information necessary to establish that the product will not expose humans to unreasonable risks when used in limited,
early-stage clinical studies”).
280See e.g. “Wikipedia,” supra note 6; Brain, supra note 14; Goodman & Gilman, supra note 4.
281Moore, supra note 129 at 1247. See also “Investigational New Drug (IND) Application Process,” supra note 279.
51investigation.”282
The initiation of the IND process is where the FDA’s regulatory role really begins:
FDA’s role in the development of a new drug begins when the drug’s sponsor (usually the
manufacturer or potential marketer) having screened the new molecule for pharmacological
activity and acute toxicity potential in animals, wants to test its diagnostic or therapeutic
potential in humans. At that point, the molecule changes in legal status under the Federal
Food, Drug, and Cosmetic Act and becomes a new drug subject to speciﬁc requirements of
the drug regulatory system.283
This really means that all of Hypo-Stim’s expensive and time-consuming preclinical testing was just to see
if the drug could possibly pass initial FDA scrutiny, and undergo later stages of clinical testing.
While the primary purpose of the IND application process is to grant a legal exemption from interstate
shipping requirements,284 a new IND “now consists of multiple sections summarizing the general investiga-
tional plan, Investigator’s Brochure (summarizing available safety and eﬃcacy information in animals and
humans, when available), protocol(s) for planned studies, chemistry/manufacturing/control information, and
pharmacology/toxicology and other information.”285 Unless the FDA decides to issue a clinical hold on the
new drug,286 “the IND goes into eﬀect and development work may proceed,” though “additional informa-
tion is then submitted periodically to the IND by the sponsor.”287 This means that Hypo-Stim’s IND will
28221 C.F.R. 312.2(b) (2003), available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=312.2.
284See Id.: (“Current Federal law requires that a drug be the subject of an approved marketing application before it is
transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical
investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the
sponsor technically obtains this exemption from the FDA”).
285Moore, supra note 129 at 1248.
286See 21 C.F.R. 312.42 (2003), available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=312.42.
287Moore, supra note 129 at 1248. Once an IND has been approved, several amendments can be made to the IND under
statutory provisions. For example, Protocol Amendments (each new protocol for clinical trials conducted under the U.S. IND)
52include detailed summaries of all the caﬀeine preclinical laboratory ﬁndings, LD50 toxicity data, as well as
explanation of caﬀeine’s positive stimulant properties.
Assuming the FDA ﬁnds the data suﬃcient to proceed with clinical trials (barring ﬁndings that the drug
is either ineﬀective or unsafe), Hypo-Stim can begin its human scientiﬁc investigation in earnest. Clinical
approval is likely to occur because caﬀeine’s level of toxicity is very mild when comparing toxic quantities
to the amount required to achieve basic stimulant eﬀects. The clinical development work process generally
has three distinct phases, the ﬁrst of which involves somewhere between twenty and eighty “healthy adult
volunteers” and requires roughly twelve to eighteen months to complete.288 The basic rationale of Phase I
study is to discover how safe the drug is as increasing dosages are applied and side eﬀects emerge.289 As
applied to Hypo-Stim’s caﬀeine testing, Phase I will likely yield mixed but positive results. It is noted that
caﬀeine causes feelings of alertness at mild dosages, and those eﬀects can be sustained with additional intake;
on the other hand, the study data likely reﬂects possible side eﬀects of nervousness and agitation.290
Since the side eﬀects of caﬀeine are generally mild and often result only at elevated dosages, Phase II studies
are likely to follow. Phase II research usually involves one-hundred to three-hundred patients “with the
disease or condition under study”; these studies often take more than two years.291 While this research
functions as an additional measure of short-term safety, its primary function is as an eﬀectiveness screen.292
For Hypo-Stim, this means that studies are conducted predominantly on sleep-deprived patients, in order to
must be submitted to the FDA under 21 C.F.R. 312.30. Information Amendments must be submitted regarding any essential
information not covered in other reports, subject to 21 C.F.R. 312.31. IND Safety Reports and Annual Reports (21 C.F.R.
312.32 and 312.33, respectively), serve to make the FDA aware of any serious or unexpected adverse events, as well as general
progress reports on the development work.
288Id. at 1249.
289See Id. In addition to basic dosage and side eﬀect measurements, Phase I generally includes studies of “pharmacokinetic
and pharmacologic actions of the drug (absorption, distribution, metabolism, and elimination information).” Id.
290See “Frequently Asked Questions About Caﬀeine,” (Dec. 2001), available at http://www.coﬀeefaq.com/caﬀaq.html.
291Moore, supra note 129 at 1249.
292See Id.
53demonstrate caﬀeine’s eﬀectiveness as a wake-up agent.293 Again, barring unforeseen problems with toxicity
or severe side eﬀects, Hypo-Stim can proceed to Phase III.
Research studies in Phase III tend to be the largest and most time consuming; they generally involve
thousands of patients, though the number varies depending on the disease or condition under study, and can
take upwards of three years to complete.294 Since more information is already available about the drug at
this point, the primary goal is to garner a large sample set with conclusive safety and eﬀectiveness ﬁndings in
order to proceed with the ﬁnal stages of FDA approval.295 Hypo-Stim is unlikely to experience a shortage of
available Americans needing a boost in the morning, and is further unlikely to uncover any surprise negative
correlations between caﬀeine intake and human health risk.
The company is therefore ready to proceed with its New Drug Application (NDA); “when the sponsor has
collected suﬃcient information from preclinical and clinical studies to provide the FDA with data for analysis
of the safety and eﬃcacy of the study drug, they submit an application for marketing.”296 The NDA process
is also very involved; it requires extensive information regarding proposed labeling, manufacturing methods
and controls, human drug interaction data, and all relevant preclinical and clinical research information.297
More importantly, Hypo-Stim will have to provide an “integrated safety summary, an integrated summary
of the beneﬁts and risks of the drug, statistical analyses, pediatric information, case report forms and
tabulations, patent information, and ﬁnancial disclosure information.”298 In other words, the company
has to have all cards on the table; all information regarding estimated eﬀective dose, side eﬀects, possible
dangerous interactions, and necessary warnings must be disclosed so that the FDA can review the drug
293It should be noted that the type of Phase II testing largely depends on the intended purpose or function of the new drug;
since caﬀeine could be widely applied to a variety of medical ailments, this hypothetical is focusing on the stimulant properties
only for sake of simplicity.
294See Moore, supra note 129 at 1249-50.
295See Id. at 1250.
296Id.
297See Id. at 1251.
298Id.
54according to its mandate.299
While this hypothetical NDA takes place without the beneﬁt of centuries of safe consumer caﬀeine use, the
new drug will likely be approved, though perhaps with stricter initial labeling requirements and warnings.
There is insuﬃcient scientiﬁc evidence to support correlations between caﬀeine and severe health risks;
further, though caﬀeine can cause borderline toxic responses in the occasional individual, the data shows
that moderate use (and even heavy use) generally results in only mild side eﬀects.300 The FDA review
process includes “medical, biopharmaceutical, [and] statistical...reviews to study and validate the sponsor’s
conclusions.”301 The FDA may request additional research and information if the agency is unsatisﬁed
by the material submitted; it may further perform inspections “to verify the data” and the integrity of
“sponsor manufacturing facilities.”302 The FDA may also consult with an expert review committee, though
the ﬁndings of the committee are non-binding.303
Assuming Hypo-Stim spends the time and money to pass caﬀeine through the entire FDA review process, a
few details remain. The FDA will likely negotiate with Hypo-Stim regarding speciﬁc product labeling, but
more importantly will decide “whether postmarketing work will be required.”304
Once a medical product receives marketing approval, there are several reasons why addi-
tional clinical studies may be needed, such as Phase IV commitments required of or agreed
to by the sponsor, pharmacoeconomic studies to assess cost/beneﬁt, investigator-initiated
studies, and quality-of-life studies.305
Assuming caﬀeine does not require any such reexamination, Hypo-Stim can ﬁnally begin to market its drug
299See “Health Information Resource Database,” supra note 131, referring to the mission of the FDA to promote safety,
eﬀectiveness, and proper labeling.
300All previously cited studies in the Paper are incorporated by reference herein.
301Moore, supra note 129 at 1251.
302See Id.
303See Rados, supra note 172.
304See Moore, supra note 129 at 1251.
55to the public, subject to the continued watch of the FDA.
The agency may have concerns about study data reﬂecting caﬀeine’s addictiveness; however, the habituation
is suﬃciently mild that it should not signiﬁcantly impede the company’s marketing of the new drug. Since
there is no known serious problem with caﬀeine use in moderate doses, any additional concerns the FDA has
can be addressed through product labeling and FDA Guidances. If long-term health study data continues
to be generally favorable, caﬀeine will continue to be approved for use as a valid drug product.
V. Conclusion: Caﬀeine – The New and Improved American Crutch
The hypothetical food additive and drug discussions are not meant to supercede a sensible policy of mod-
erated intake.306 To paraphrase an old American saying, “too much of a good thing can be bad for your
health.” This statement is valid with regard to almost anything, and caﬀeine intake is probably no excep-
tion. Though the FDA cannot absolutely guarantee that every consumer will exercise moderation of caﬀeine
intake, the same could be said for any widely available food and over-the-counter drug product.
Fortunately, the FDA arguably has much less to worry about with regard to caﬀeine regulation nowadays
than it did in 1980 when negative caﬀeine correlations were ﬁrst being asserted. The majority of medical
306One source summarizes the rationales for the FDA review processes as follows: (“In the U.S., the review of a new drug
application serves many purposes. It is a public scientiﬁc document reﬂecting how a regulatory agency interprets information
submitted for market approval of a drug. It provides a public record which needs to be ‘correct, coherent, well-organized,
and credible’. It also shows the scientiﬁc aspects of the review. The goal of an application review is to determine if the data
submitted supports proposed labeling claims and whether or not there is substantial evidence of eﬃcacy and evidence that the
drug is safe”). Anello, supra note 270. Since caﬀeine arguably satisﬁes all of these ideas, there is no signiﬁcant reason to assume
it is unworthy of current levels of consumer intake.
56studies conducted in the intervening period generally tend to demonstrate that moderate use of caﬀeine, both
in foods and in drugs, poses no signiﬁcant health risks to most consumers, representing a turnaround from
earlier ﬁndings. Further, research is beginning to show (with gradually increasing levels of persuasiveness)
that caﬀeine intake at varying higher levels is linked to a number of potential health beneﬁts.
While it is admittedly too early to assume that a heavy daily intake of “Starbucks” will help prevent the onset
of diseases such as Parkinson’s and type-2 diabetes, the FDA cannot ignore the positive correlations being
drawn between caﬀeine consumption and human health. More importantly, given the demanding amount
of time and money required to supervise the creation of new food additives and drugs, the FDA need not
waste additional precious regulatory resources on a substance that has been safely ingested for hundreds, if
not thousands of years. There is no additional need for FDA regulation of caﬀeine with respect to food or
drug products.
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